## List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAFP</td>
<td>American Academy of Family Physicians</td>
</tr>
<tr>
<td>Add Health</td>
<td>National Longitudinal Study of Adolescent Health</td>
</tr>
<tr>
<td>ADHD</td>
<td>attention deficit hyperactivity disorder</td>
</tr>
<tr>
<td>AFRO</td>
<td>WHO Africa</td>
</tr>
<tr>
<td>AHA</td>
<td>American Heart Association</td>
</tr>
<tr>
<td>ALA</td>
<td>American Lung Association</td>
</tr>
<tr>
<td>AMA</td>
<td>American Medical Association</td>
</tr>
<tr>
<td>ASSIST</td>
<td>American Stop Smoking Intervention Study</td>
</tr>
<tr>
<td>B&amp;W</td>
<td>Brown &amp; Williamson Tobacco Corporation</td>
</tr>
<tr>
<td>BAT</td>
<td>British American Tobacco</td>
</tr>
<tr>
<td>BHR</td>
<td>bronchial hyperresponsiveness</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>BRFSS</td>
<td>Behavioral Risk Factor Surveillance System</td>
</tr>
<tr>
<td>CAI</td>
<td>computer-assisted interviewing</td>
</tr>
<tr>
<td>CARDIA</td>
<td>Coronary Artery Risk Development in Young Adults</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CEO</td>
<td>chief executive officer</td>
</tr>
<tr>
<td>CHIPS</td>
<td>Choosing Healthy Influences for a Positive Self</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>COMMIT</td>
<td>Community Intervention Trial for Smoking Cessation</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CSAP</td>
<td>Center for Substance Abuse Prevention</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>D.A.R.E.</td>
<td>Drug Abuse Resistance Education</td>
</tr>
<tr>
<td>DSM-IV</td>
<td><em>Diagnostic and Statistical Manual of Mental Disorders- 4th edition</em></td>
</tr>
<tr>
<td>DVD</td>
<td>digital video disc</td>
</tr>
<tr>
<td>DZ</td>
<td>dizygotic</td>
</tr>
<tr>
<td>EDI</td>
<td>Eating Disorders Inventory</td>
</tr>
<tr>
<td>ED-NOS</td>
<td>eating disorders-not otherwise specified</td>
</tr>
<tr>
<td>EMRO</td>
<td>WHO Eastern Mediterranean</td>
</tr>
<tr>
<td>ES</td>
<td>effect size</td>
</tr>
<tr>
<td>ESFA</td>
<td>European Smoking Prevention Framework Approach</td>
</tr>
<tr>
<td>ESPAD</td>
<td>European School Survey Project on Alcohol and Other Drugs</td>
</tr>
<tr>
<td>EURO</td>
<td>WHO Europe</td>
</tr>
<tr>
<td>FCC</td>
<td>Federal Communications Commission</td>
</tr>
<tr>
<td>FCP</td>
<td>Full Court Press</td>
</tr>
<tr>
<td>FCTC</td>
<td>Framework Convention for Tobacco Control</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FEF</td>
<td>forced expiratory flow</td>
</tr>
<tr>
<td>FEF_{25–75}</td>
<td>FEF between 25% and 75% of forced vital capacity</td>
</tr>
<tr>
<td>FEV\textsubscript{1}</td>
<td>forced expiratory volume in 1 second</td>
</tr>
<tr>
<td>FLAVOR</td>
<td>Fun Learning about Vitality, Origin, and Respect</td>
</tr>
<tr>
<td>FOK</td>
<td>Focus on Kids</td>
</tr>
<tr>
<td>FTC</td>
<td>Federal Trade Commission</td>
</tr>
<tr>
<td>FTND</td>
<td>Fagerström Test of Nicotine Dependence</td>
</tr>
<tr>
<td>FTQ</td>
<td>Fagerström Tolerance Questionnaire</td>
</tr>
<tr>
<td>FVC</td>
<td>forced vital capacity</td>
</tr>
<tr>
<td>g</td>
<td>gram</td>
</tr>
<tr>
<td>GABA</td>
<td>gamma-aminobutyric acid</td>
</tr>
<tr>
<td>GNAT</td>
<td>Go/No-go Association Test</td>
</tr>
<tr>
<td>GRP</td>
<td>gross rating point</td>
</tr>
<tr>
<td>GTSS</td>
<td>Global Tobacco Surveillance System</td>
</tr>
<tr>
<td>GYTS</td>
<td>Global Youth Tobacco Survey</td>
</tr>
<tr>
<td>HDL</td>
<td>high-density lipoprotein</td>
</tr>
<tr>
<td>HONC</td>
<td>Hooked on Nicotine Checklist</td>
</tr>
<tr>
<td>HSI</td>
<td>Heaviness of Smoking Index</td>
</tr>
<tr>
<td>IARC</td>
<td>International Agency for Research on Cancer</td>
</tr>
<tr>
<td>IAT</td>
<td>Implicit Association Test</td>
</tr>
<tr>
<td>ICC</td>
<td>intraclass correlation coefficient</td>
</tr>
<tr>
<td>ICV</td>
<td>Internet cigarette vendors</td>
</tr>
<tr>
<td>IMBC</td>
<td>Integrated Model of Behavior Change</td>
</tr>
<tr>
<td>ImpACT</td>
<td>Informed Parents and Kids Together</td>
</tr>
<tr>
<td>IMPACT</td>
<td>Initiatives to Mobilize for the Prevention and Control of Tobacco Use</td>
</tr>
<tr>
<td>IOM</td>
<td>Institute of Medicine</td>
</tr>
<tr>
<td>IRR</td>
<td>incidence rate ratio</td>
</tr>
<tr>
<td>ISAAC</td>
<td>International Study of Asthma and Allergies in Childhood</td>
</tr>
<tr>
<td>ISFP</td>
<td>Iowa Strengthening Families Program</td>
</tr>
<tr>
<td>ITT</td>
<td>intent to treat</td>
</tr>
<tr>
<td>kg</td>
<td>kilogram</td>
</tr>
<tr>
<td>L</td>
<td>liter</td>
</tr>
<tr>
<td>LCA</td>
<td>latent class analysis</td>
</tr>
<tr>
<td>LDL</td>
<td>low-density lipoprotein</td>
</tr>
<tr>
<td>Legacy</td>
<td>American Legacy Foundation</td>
</tr>
<tr>
<td>LST</td>
<td>LifeSkills Training</td>
</tr>
<tr>
<td>LTA</td>
<td>latent transition analysis</td>
</tr>
</tbody>
</table>
List of Tables and Figures

Chapter 1
Introduction, Summary, and Conclusions

Table 1.1 Four-level hierarchy for classifying the strength of causal inferences from available evidence 8

Chapter 2
The Health Consequences of Tobacco Use Among Young People

Table 2.1a Conclusions from previous Surgeon General’s reports on the adverse effects of tobacco use and exposure to secondhand smoke in children and young adults 16

Table 2.1b Level of certainty of causality reported in the 2004 and 2006 Surgeon General’s reports 20

Table 2.2 Studies assessing belief that smoking controls body weight 33

Table 2.3 Studies assessing use of smoking to control body weight (school and population surveys) 46

Table 2.4 Studies assessing use of smoking to control body weight (clinical samples) 61

Table 2.5 Studies assessing association between smoking and body weight 71

Table 2.6 Studies assessing change in weight following smoking cessation 76

Table 2.7 Studies assessing change in weight following smoking initiation 78

Table 2.8 Longitudinal studies on the association between smoking and maximum attained level of forced expiratory volume in one second (FEV1), rates of growth, age of plateau in lung function, and age of onset of decline in lung function 81

Table 2.9 Cross-sectional studies on the association of smoking with childhood cough, bronchitis symptoms, shortness of breath, wheeze, and asthma 89

Table 2.10 Longitudinal studies on the association of smoking with cough, bronchitis symptoms, shortness of breath, wheeze, and asthma in cohorts followed since childhood 92

Table 2.11 Relationship between tobacco use and atherosclerosis or subclinical atherosclerosis 98

Table 2.12 Endothelial dysfunction in young smokers 103

Figure 2.1 Average age when a whole cigarette was smoked for the first time among 9th- to 12th-grade youth; Youth Risk Behavior Survey (YRBS) 1991–2009; United States 22

Figure 2.2 Body mass index (BMI) differences among smokers and nonsmokers by age group 75

Figure 2.3 Gender-specific effects of smoking on level of pulmonary function in youth 10–18 years of age 84

Figure 2.4 Mean rates of pulmonary function growth by age, gender, and category of smoking 85

Figure 2.5 Relationship of age and the number of cardiovascular risk factors with severity of atherosclerosis in the right coronary artery in males in the Pathobiological Determinants of Atherosclerosis in Youth study 100

Chapter 3
The Epidemiology of Tobacco Use Among Young People in the United States and Worldwide

Table 3.1 Sources of national data on tobacco use among young people; United States and worldwide 132

Table 3.2 Cumulative percentages of recalled age at which a respondent first used a cigarette and began smoking daily, by smoking status among 30- to 39-year-olds; National Survey on Drug Use and Health (NSDUH) 2010; United States 136

Table 3.3a Percentage of high school students and middle school students who currently smoke cigarettes, by gender and race/ethnicity; National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 137

Table 3.3b Percentage of young adults (18–25 years old) who currently smoke cigarettes, by gender and race/ethnicity; National Survey on Drug Use and Health NDSUH (2010); United States 138
Table 3.4a  Percentage of high school students and middle school students who currently use smokeless tobacco, by gender and race/ethnicity and age/grade; Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States  

Table 3.4b  Percentage of young adults (18–25 years old) who currently use smokeless tobacco, by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2010; United States  

Table 3.5a  Percentage of high school students and middle school students who currently smoke cigars, by gender and race/ethnicity and age/grade; Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States  

Table 3.5b  Percentage of young adults (18–25 years old) who currently smoke cigars, by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2010; United States  

Figure 3.1  Percentage of recalled age at which adult smokers first tried a cigarette and began smoking daily, among 30- to 39-year-old adult smokers, by smoking status; National Survey on Drug Use and Health (NSDUH) 2010; United States  

Figure 3.2  Percentage of middle school 8th graders, high school seniors, young adults (18–25 years of age), and adults (≥ 26 years of age) who currently smoke cigarettes; National Youth Tobacco Survey (NYTS) 2009, and National Survey on Drug Use and Health (NSDUH) 2010; United States  

Figure 3.3  Trends in the prevalence of current cigarette smoking over time among high school students, by gender and race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1991–2009; United States  

Figure 3.4  Current high school cigarette smoking and projected rates if decline had continued; National Youth Risk Behavior Survey (YRBS) 1991–2009; United States  

Figure 3.5  Trends in the initiation of cigarette smoking over time among young adults (18–25 years-old), by gender and race/ethnicity and age/grade; National Survey on Drug Use and Health (NSDUH) 2006 and 2010; United States  

Figure 3.6  Trends in prevalence of current smokeless tobacco use over time among high school students (National Youth Risk Behavior Survey [YRBS]) and high school seniors (Monitoring the Future [MTF]), by gender and race/ethnicity; YRBS 1995–2009 and MTF 1987 (or 1993)–2010; United States  

Figure 3.7  Trends in the initiation of smokeless tobacco use over time among young adults (18- to 25-year olds), by gender and by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006 and 2010; United States  

Figure 3.8  Trends in the prevalence of current cigar smoking over time among high school students, by gender and by race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1997–2009; United States  

Figure 3.9  Trends in the initiation of cigar smoking over time among young adults (18- to 25-year-olds), by gender and by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006 and 2010; United States  

Figure 3.10  Percentage of current cigarette smoking among adolescents (12- to 17-year-olds) and young adults (18- to 25-year-olds), by race/ethnicity and by gender; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States  

Figure 3.11  Percentage of current cigarette smoking among 8th, 10th, and 12th graders, by parental education (as a proxy for socioeconomic status) and grade level; Monitoring the Future (MTS) 2002–2007; United States  

Figure 3.12  Percentage of current cigarette smoking among young adults (18- to 25-years-olds), by education and employment (as proxies for socioeconomic status); National Survey on Drug Use and Health (NSDUH) 2010; United States  

Figure 3.13  Prevalence of current use of multiple tobacco products among high school males who use tobacco; National Youth Risk Behavior Survey (YRBS) 2009; United States  

Figure 3.14  Percentage of youth 13–15 years of age who currently use any tobacco product, by gender; Global Youth Tobacco Survey (GYTS) 1999–2009; Brazil (Rio de Janeiro), China (Macao), India, Russian Federation, South Africa, and the Syrian Arab Republic
Chapter 3 Appendices

The Epidemiology of Tobacco Use Among Young People in the United States and Worldwide

Table 3.1.1 Percentage of young people who have ever smoked cigarettes, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 227

Table 3.1.2 Percentage of young people who currently smoke cigarettes, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 229

Table 3.1.3 Percentage of current cigarette use among 12- to 17-year-olds, by race/ethnicity and gender; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 231

Table 3.1.4 Percentage of current cigarette use among 18- to 25-year-olds, by race/ethnicity and gender; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 232

Table 3.1.5 Percentage of current cigarette smoking, by various sociodemographic risk factors among 8th, 10th, and 12th graders; Monitoring the Future (MTF) 2002–2007; United States 233

Table 3.1.6 Percentage of frequent cigarette smoking, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 234

Table 3.1.7 Percentage of heavy cigarette smoking, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, and National Youth Tobacco Survey (NYTS) 2009; United States 236

Table 3.1.8 Percentage distribution of smoking intensity among 9th–12th graders, by the number of cigarettes smoked per day during the 30 days preceding the survey; National Youth Risk Behavior Survey (YRBS) 2009; United States 237

Table 3.1.9 Cumulative percentages of recalled age at which a respondent first used a cigarette and began smoking daily, by smoking status among 30- to 39-year-olds; National Survey on Drug Use and Health (NSDUH) 2010; United States 238

Table 3.1.10 Percentage distribution of cigarette brands that 12- to 17-year-olds who were current smokers preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 239

Table 3.1.11 Percentage distribution of cigarette brands that young adults 18–25 years of age who were current smokers preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 241

Table 3.1.12 Percentage of 12- to 17-year-olds who had never smoked but were susceptible to starting to smoke cigarettes, by race/ethnicity and gender; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 243

Table 3.1.13 Percentage of 12- to 17-year-olds who had never smoked but were susceptible to starting to smoke cigarettes, by race/ethnicity and gender; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 244
Table 3.1.14  | Age or grade when respondents first began smoking daily, among 17- to 18-year-olds who had completed 11th grade, National Survey on Drug Use and Health (NSDUH) 2010; and among 12th graders, Monitoring the Future (MTF) 2010; United States  244

Table 3.1.15  | Distribution of developmental trajectories of cigarette smoking across adolescence and young adulthood, 11–26 years of age, by gender and race/ethnicity; National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States  245

Table 3.1.16  | Distribution of developmental trajectories of cigarette smoking across adolescence and young adulthood, 11–26 years of age, by level of nicotine dependence (Fagerström scale); National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States  245

Table 3.1.17  | Percentage of young people (12–14 years of age at Wave I and 19–21 years of age at Wave III) who were characterized as never smokers, current smokers, or former smokers, by gender and race/ethnicity; National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States  246

Table 3.1.18  | Probability of transitioning from one stage of cigarette smoking to another, from Wave I (12–14 years of age) to Wave III (19–21 years of age); National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States  246

Table 3.1.19  | Percentage of young people (15–18 years of age at Wave I and 22–25 years of age at Wave III) who were characterized as never smokers, former smokers, nondaily smokers, or daily smokers, by gender and race/ethnicity; National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States  247

Table 3.1.20  | Probability of transitioning from one stage of cigarette smoking to another, from Wave I (15–18 years of age) to Wave III (22–25 years of age); National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States  248

Table 3.1.21  | Predicted likelihood (%) of smoking in young adulthood (5 years later), by intensity of smoking among 1996–2001 high school seniors; Monitoring the Future (MTF) 1996–2007; United States  249

Table 3.1.22  | Intensity of smoking (%) in young adulthood (5–6 years later), by intensity of smoking among 1996–2001 high school seniors; Monitoring the Future (MTF) 1996–2007; United States  249

Table 3.1.23  | Percentage change in the direction of intensity of smoking between senior year of high school and young adulthood (5–6 years later), among 1996–2001 high school seniors; Monitoring the Future (MTF) 1996–2007; United States  250

Table 3.1.24  | Intensity of smoking in young adulthood (5–6 years later), by intensity of smoking in senior year of high school and expectation to smoke within 5 years, among 1996–2001 high school seniors; Monitoring the Future (MTF) 1996–2007; United States  251

Table 3.1.25  | Indicators of cigarette smoking and nicotine dependence among 12- to 17-year-olds smoking cigarettes during the previous 30 days; National Survey on Drug Use and Health (NSDUH) 2007–2010; United States  252

Table 3.1.26  | Indicators of cigarette smoking and nicotine dependence among 18- to 25-year-olds smoking cigarettes during the previous 30 days; National Survey on Drug Use and Health (NSDUH) 2007–2010; United States  254

Table 3.1.27  | Indicators of cigarette use and nicotine dependence among adults 26 years of age or older smoking cigarettes during the previous 30 days; National Survey on Drug Use and Health (NSDUH) 2007–2010; United States  256

Table 3.1.28  | Percentage of high school seniors who were smokers during the previous month, by gender and race/ethnicity; Monitoring the Future (MTF) 1976–2007; United States  257

Table 3.1.29  | Percentage of 20- to 44-year-olds who identified themselves as current smokers, by age group, race/ethnicity, and gender; National Health Interview Surveys (NHIS) 1978–2009; United States  258

Table 3.1.30  | Trends in the initiation of cigarette smoking over time among 12- to 17-year-olds at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States  261
Preventing Tobacco Use Among Youth and Young Adults

Table 3.1.31 Trends in the initiation of cigarette smoking over time among 18- to 25-year-olds at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 261

Table 3.1.32 Percentage of high school senior smokers who answered “yes” to questions about interest in quitting smoking and attempts to quit smoking, by frequency of smoking during the past 30 days; Monitoring the Future (MTF) 1990–2009; United States 262

Table 3.1.33 Prevalence of cigarette smoking among users of smokeless tobacco and among users of drugs (e.g., alcohol, marijuana, cocaine, and inhalants) and prevalence of other drug use among cigarette smokers, among male high school seniors; Monitoring the Future (MTF) 2002–2007; United States 262

Table 3.1.34 Prevalence of cigarette smoking among users of other drugs (e.g., alcohol, marijuana, cocaine, and inhalants) and prevalence of other drug use by cigarette smokers, among female high school seniors; Monitoring the Future (MTF) 2002–2007; United States 263

Table 3.1.35 Percentage distribution of grade in which high school seniors first (if ever) used cigarettes or alcohol, or both; Monitoring the Future (MTF) 2002–2007; United States 263

Table 3.1.36 Percentage distribution of grade in which high school seniors first (if ever) used cigarettes or marijuana, or both; Monitoring the Future (MTF) 2002–2007; United States 264

Table 3.1.37 Percentage distribution of grade in which high school seniors first (if ever) used cigarettes or cocaine, or both; Monitoring the Future (MTF) 2002–2007; United States 264

Table 3.1.38 Body mass index by smoking status/frequency among high school seniors, by gender and race/ethnicity; National Youth Risk Behavior Survey (YRBS) 2003–2009; United States 265

Table 3.1.39 Percentage of 12- to 17-year-olds and 18- to 25-year-olds who have experienced a major depressive episode, by smoking status/frequency, gender, and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2009–2010; United States 266

Table 3.1.40 Percentage of young people who have ever used smokeless tobacco, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, and National Youth Tobacco Survey (NYTS) 2009; United States 267

Table 3.1.41 Percentage of young people who currently use smokeless tobacco, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 269

Table 3.1.42 Prevalence of 8th-, 10th-, and 12th-grade males who currently use smokeless tobacco, by various sociodemographic risk factors; Monitoring the Future (MTF) 2002–2007; United States 271

Table 3.1.43 Age at which high school senior respondents first used smokeless tobacco or cigars; National Youth Tobacco Survey (NYTS) 2009; United States 272

Table 3.1.44 Percentage distribution of smokeless tobacco brands that youth 12–17 years of age who were current users of smokeless tobacco preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 273

Table 3.1.45 Share of the smokeless tobacco market in 2008, by type and brand; the Maxwell Report; United States 275

Table 3.1.46 Prevalence of smokeless tobacco use among cigarette smokers and users of drugs and prevalence of cigarette smoking and drug use among users of smokeless tobacco in the past 30 days, among male high school seniors; Monitoring the Future (MTF) 2002–2007 and National Survey on Drug Use and Health (NSDUH) 2010; United States 276

Table 3.1.47 Percentage distribution of smokeless tobacco brands that young adults 18–25 years of age who were current users of smokeless preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 277

Table 3.1.48 Percentage of young people who have ever smoked cigars, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010 and National Youth Tobacco Survey (NYTS) 2009; United States 279
Table 3.1.49  Percentage of young people and young adults 18–25 years of age who currently smoke cigars by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States  280

Table 3.1.50  Percentage distribution of cigar brands that youth 12–17 years of age who currently smoke cigars preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States  282

Table 3.1.51  Share of cigar market in 2008, by brand; the Maxwell Report; United States  284

Table 3.1.52  Percentage distribution of cigar brands that young adults, 18–25 years of age who currently smoke cigars preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States  287

Table 3.1.53  Prevalence of cigar use among users of other tobacco products and drugs and prevalence of other tobacco products and drug use among cigar users, among youth 12–17 years of age; National Survey on Drug Use and Health (NSDUH) 2010; United States  288

Table 3.1.54  Prevalence of the use of bidis and kretek among youth in grades 6–12, by gender and race/ethnicity; National Youth Tobacco Survey (NYTS) 2009; United States  289

Table 3.1.55  Percentage of young people currently using both cigarettes and smokeless tobacco, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States  291

Table 3.1.56  Percentage distribution of grade in which male high school seniors first (if ever) used smokeless tobacco and cigarettes; Monitoring the Future (MTF) 2002–2007; United States  291

Table 3.1.57  Trends in the initiation of smokeless tobacco use over time among youth 12–17 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States  291

Table 3.1.58  Trends in the initiation of smokeless tobacco use over time among young adults 18–25 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States  292

Table 3.1.59  Trends in the initiation of cigar smoking over time among youth 12–17 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States  293

Table 3.1.60  Trends in the initiation of cigar smoking over time among young adults 18–25 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States  293

Table 3.1.61  Trends in the initiation of cigarettes, smokeless tobacco, and cigars over time among youth 12–17 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States  294

Table 3.1.62  Trends in the initiation of cigarettes, smokeless tobacco, or cigars over time among young adults 18–25 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States  294

Table 3.1.63  Percentage of youth 13–15 years of age who have ever smoked cigarettes, who first tried smoking when younger than 10 years of age, and among never smokers who are susceptible to starting to smoke within the next year, by gender; Global Youth Tobacco Survey 1999–2009; worldwide  295

Table 3.1.64  Percentage of youth 13–15 years of age who have smoked cigarettes on 1 or more days during the past 30 days, and of those who have smoked cigarettes on 20 or more of the past 30 days, by gender; Global Youth Tobacco Survey 1999–2009; worldwide  306

Table 3.1.65  Percentage of youth 13–15 years of age who currently smoke and always feel like having a cigarette first thing in the morning, who want to stop smoking, and who have tried to stop smoking during the past year, by gender; Global Youth Tobacco Survey 1999–2009; worldwide  317
Table 3.1.66  Percentage of youth 13–15 years of age who have used any form of tobacco during the past 30 days and who have used any form of tobacco other than cigarettes during the past 30 days, by gender; Global Youth Tobacco Survey (GYTS) 1999–2009; worldwide 328

Table 3.1.67  Percentage of youth 16 years of age who have smoked 40 or more cigarettes in their lifetime and who currently smoke cigarettes, overall and by gender; European School Survey Project on Alcohol and other Drugs (ESPAD) 2007; Europe 337

Figure 3.1.1  Percentage who currently smoke cigarettes, by age group and state; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 339

Figure 3.1.2  Percentage who currently smoke cigarettes, by age group, state, and gender; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 341

Figure 3.1.3  Prevalence of current cigarette smoking among 12- to 17-year-olds and those 26 years of age or older, by state; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 344

Figure 3.1.4  Distribution of developmental trajectories of cigarette smoking across adolescence and young adulthood, from 11 to 26 years of age, overall; National Longitudinal Study of Adolescent Health (Add Health) 1994–1996, 2001–2002; United States 344

Figure 3.1.5  Trends in prevalence (%) of ever smoking among young people over time, by grade level and gender; Monitoring the Future (MTF) 1975–2010; United States 345

Figure 3.1.6  Trends in prevalence (%) of ever smoking among young people, by grade level and race/ethnicity; Monitoring the Future (MTF) 1976–2010 and National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 347

Figure 3.1.7  Trends in prevalence (%) of ever smoking and current smoking among 9th–12th grade students, by gender; National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 349

Figure 3.1.8  Trends in prevalence (%) of current smoking among young people over time, by grade level; Monitoring the Future (MTF) 1975–2010; United States 350

Figure 3.1.9  Trends in prevalence (%) of current cigarette smoking among young people over time, by grade level and race/ethnicity; Monitoring the Future (MTF) 1976–2010 and National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 352

Figure 3.1.10  Trends in the prevalence (%) of current smoking among 9th- to 12th-grade students, by state; Youth Risk Behavior Survey (YRBS) 1991–2009; United States 354

Figure 3.1.11  Trends in prevalence (%) of cigarette smoking among Hispanics, Blacks, and Whites, by age group; National Health Interview Survey (NHIS) 1978–2009; United States 359

Figure 3.1.12  Trends in prevalence (%) of cigarette smoking among persons 20 years of age or older, by age group and race/ethnicity; National Health Interview Survey (NHIS) 1978–2009; United States 362

Figure 3.1.13  Past-month cigarette use among young adults (18–25 years of age), by gender; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 363

Figure 3.1.14  Past-month cigarette use among young adults (18–25 years of age), by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 364

Figure 3.1.15  Past-month cigarette use among young adults (18–25 years of age), by poverty level; National Survey on Drug Use and Health (NSDUH) 2005–2010; United States 364

Figure 3.1.16  Trends in the intensity of smoking among high school seniors; Monitoring the Future (MTF) 1976–2010; United States 365

Figure 3.1.17  Trends in cigarette brand preference for the top five cigarette brands among 12- to 17-year-olds who are current smokers, by gender; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 366

Figure 3.1.18  Trends in cigarette brand preference for the top five cigarette brands among 18- to 25-year-olds who are current smokers, by gender; National Survey on Drug Use & Health (NSDUH) 2002–2010; United States 367

Figure 3.1.19  Trends in the percentage of former smokers among ever regular smokers who are high school seniors, over time, by gender; Monitoring the Future (MTF) 1976–2010; United States 368
Figure 3.1.20 Trends in the percentage of high school seniors who believe that smoking is a serious health risk and percentage of high school seniors who have ever smoked; Monitoring the Future (MTF) 1975–2010; United States 368

Figure 3.1.21 Trends in the percentage of young people who believe smoking is a “dirty habit,” by grade level; Monitoring the Future (MTF) 1991–2010; United States 369

Figure 3.1.22 Trends in the percentage of high school seniors who believe their close friends would disapprove of their smoking one or more packs of cigarettes per day; Monitoring the Future (MTF) 1979–2010; United States 369

Figure 3.1.23 Trends in the percentage of high school seniors who prefer to date nonsmokers, over time, by gender; Monitoring the Future (MTF) 1981–2010; United States 370

Figure 3.1.24 Trends in the percentage of high school seniors who prefer to date nonsmokers, over time, by race/ethnicity; Monitoring the Future (MTF) 1981–2010; United States 370

Figure 3.1.25 Trends in the percentage of young people who do not mind being around people who smoke, by grade level; Monitoring the Future (MTF) 1991–2010; United States 371

Figure 3.1.26 Grade in which high school seniors had first tried cigarettes, smokeless tobacco, alcohol, marijuana, and cocaine among respondents who had ever used these substances by 12th grade; Monitoring the Future (MTF) 2002–2007; United States 371

Figure 3.1.27 Trends in health risk outcomes and behaviors among high school senior cigarette smokers and nonsmokers; National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 372

Figure 3.1.28 Percentage who currently use smokeless tobacco, by age group and state; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 382

Figure 3.1.29 Percentage who currently use smokeless tobacco, by age group, state, and gender; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 384

Figure 3.1.30 Past-month smokeless tobacco use among young adults (18–25 years of age), by gender; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 387

Figure 3.1.31 Past-month smokeless tobacco use among young adults (18–25 years of age), by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 387

Figure 3.1.32 Past-month smokeless tobacco use among young adults (18–25 years of age), by poverty level; National Survey on Drug Use and Health (NSDUH) 2005–2010; United States 388

Figure 3.1.33 Trends in prevalence (%) of current smokeless tobacco use among young people, by grade level; Monitoring the Future (MTF) 1986–2010 and National Youth Risk Behavior Survey (YRBS) 1995–2009; United States 389

Figure 3.1.34 Trends in prevalence (%) of current smokeless tobacco use among males, by grade level and race/ethnicity; Monitoring the Future (MTF) 1987–2010; United States 391

Figure 3.1.35 Trends in the percentage of young people who believe that smokeless tobacco is a serious health risk and in the percentage of high school seniors who have ever used smokeless tobacco; Monitoring the Future (MTF) 1986–2010; United States 392

Figure 3.1.36 Percentage who currently smoke cigars, by age group and state; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 393

Figure 3.1.37 Past-month cigar use among young adults (18–25 years of age), by gender; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 394

Figure 3.1.38 Past-month cigar use among young adults (18–25 years of age), by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 395

Figure 3.1.39 Past-month cigar use among young adults (18–25 years of age), by poverty level; National Survey on Drug Use and Health (NSDUH) 2005–2010; United States 395

Figure 3.1.40 Percentage who currently smoke cigars, by age group, state, and gender; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 396

Figure 3.1.41 Trends in prevalence (%) of cigar use among young people, by gender and by race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1997–2009; United States 399
Figure 3.1.42  Trends in current use of bidis and kretek among young people, by gender and by race/ethnicity; National Youth Tobacco Survey (NYTS) for 1999, 2000, 2002, 2004, 2006, and 2009; United States 400

Figure 3.1.43  Prevalence of current use of multiple tobacco products among all males of high school age and only those males of high school age who report using tobacco; National Survey on Drug Use and Health (NSDUH) 2010 and National Youth Risk Behavior Survey (YRBS) 2009; United States 404

Figure 3.1.44  Trends in prevalence (%) of current use of two or more different tobacco products among students reporting any tobacco use, by gender and by race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1997–2009; United States 405

Figure 3.1.45  Percentage of 13- to 15-year-olds who have ever smoked cigarettes, by gender; Global Youth Tobacco Survey 1999–2007; worldwide 407

Figure 3.1.46  Percentage of 13- to 15-year-olds who currently smoke cigarettes, by gender; Global Youth Tobacco Survey 1999–2007; worldwide 409

Figure 3.1.47  Percentage of 13- to 15-year-olds who currently smoke and want to stop smoking, by gender; Global Youth Tobacco Survey 1999–2007; worldwide 411

Figure 3.1.48  Percentage of 13- to 15-year-olds who currently use other forms of tobacco than cigarettes, by gender; Global Youth Tobacco Survey 1999–2007; worldwide 413

Table 3.2.1  Measures of tobacco use, by source, 2008 and 2009 questionnaires; United States and worldwide 415

Chapter 4  
Social, Environmental, Cognitive, and Genetic Influences on the Use of Tobacco Among Youth

Table 4.1  Prevalence of smoking in previous month among adolescents aged 16–19 years who have not completed 12th grade, by enrollment status in school; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 436

Chapter 5  
The Tobacco Industry’s Influences on the Use of Tobacco Among Youth

Table 5.1  Cigarette company marketing activities reported to the Federal Trade Commission (FTC) 489

Table 5.2  Detailed expenditures for cigarette marketing, in thousands of dollars, 2002–2008 492

Table 5.3  Cigarette company marketing expenditures, by major category, in millions of dollars, 1963–2008 495

Table 5.4  Cigarette company marketing expenditures, percentage of total by major category, in millions of dollars, 1975–2008 497

Table 5.5  Cigarette company marketing expenditures, by major category, in millions of dollars, 1975–2008 499

Table 5.6  Detailed expenditures for smokeless tobacco marketing, in thousands of dollars, 2002–2008 501

Table 5.7  Smokeless tobacco company marketing expenditures, by major category, in millions of dollars, 1988–2008 504

Table 5.8  Smokeless tobacco company marketing expenditures, by major category, in millions of dollars, 1988–2008 505

Table 5.9  Smokeless tobacco company marketing expenditures, percentage of total by major category, in millions of dollars, 1988–2008 506

Table 5.10  Controlled-exposure studies examining televised messages in the tobacco industry’s campaign to prevent youth smoking 559

Table 5.11  Naturalistic studies examining the effect of televised campaigns of the tobacco industry on preventing youth smoking 562

Table 5.12  Content analyses of movies in studies published since 2005 572

Table 5.13  Population-based studies assessing the relation between exposure to movie smoking and smoking among young people 576

Table 5.14  Population-based studies assessing the relation between parental restrictions on viewing R-rated movies and smoking among adolescents 594
Chapter 6
Efforts to Prevent and Reduce Tobacco Use Among Young People

Table 6.1 Summaries of controlled field trials of community-based mass media programs, by review(s) 638

Table 6.2 Summary of longitudinal and cross-sectional population-based studies examining the effects on youth of mass media antismoking campaigns 647

Table 6.3 Controlled exposure and naturalistic exposure studies examining the relative effectiveness of different advertising messages for youth 669

Table 6.4 Budgeted state funding of tobacco control programs in fiscal year 2011 in relation to funding levels recommended by the Centers for Disease Control and Prevention (CDC) 695

Table 6.5 Federal cigarette excise taxes, selected dates, 1993–2009 698

Table 6.6 Federal tax rates on other tobacco products, selected dates, 1993–2009 698

Table 6.7 State cigarette excise taxes (dollars per pack) and sales tax rate applied to cigarettes 700

Table 6.8 Descriptions and effect sizes (expressed as relative improvements) of parenting and family interventions for preventing use of tobacco among adolescents 722

Table 6.9 Studies of the effectiveness of school-based interventions to reduce tobacco use 735

Table 6.10 Studies of the effectiveness of multicomponent interventions that include school-based programs to reduce tobacco use 777

Table 6.11 Studies on smoking cessation among youth 794

Table 6.12 Youth cessation treatment means, 2006 and 2007 analyses, stratified by duration of follow-up 799

Table 6.13 Youth cessation treatment means, 2006 and 2007 analyses, stratified by theory 799

Table 6.14 Youth cessation treatment means, 2006 and 2007 analyses, stratified by modality 799

Figure 5.1 Structure supporting the effect of marketing on youth smoking based on the Theory of Triadic Influence 510

Figure 5.2 Cigarette prices and cigarette sales, United States, 1970–2011 525

Figure 5.3 Cigarette prices and prevalence of youth smoking by grade in school, United States, 1991–2011 526

Figure 5.4 Camel crush package and filter flavor pellet 538

Figure 5.5 Graduation strategy designed to encourage new smokeless tobacco users to start with products with low free nicotine content and progress to others with higher levels of free nicotine 540

Figure 5.6 Tobacco industry paradigm shift 553

Figure 5.7 Actor engaging an actress with a cigarette 565

Figure 5.8 “SHOUT, Mr. Tracy!”: actor enjoying a cigarette 566

Figure 5.9 Proportion of movies containing tobacco brand appearances in the top 100 box office hits released each year, 1996–2008 567

Figure 5.10 (A) Occurrences of smoking in highest-grossing movies, 1990–2007, and (B) smoking among eighth graders, 1991–2007, in the United States 568

Figure 5.11 Comparison of the trend for proportion of 5-minute movie segments with tobacco (means for 15 of the top 30 box office hits from 1950 to 2005) and per capita cigarette consumption among adults, 1950–2005, in the United States 570

Figure 5.12 Summary and meta-analysis of studies on the association between exposure to movie smoking and smoking among adolescents and young adults 590

Figure 5.13 Shape of the crude dose-response relation between exposure to movie smoking and smoking onset for German and U.S. samples of adolescents 591

Figure 5.14 Summary of results for studies on the association between parental movie restrictions and smoking among early adolescents 596
Table 6.15  Youth cessation treatment means, 2006 and 2007 analyses, stratified by number of sessions  799

Table 6.16  Studies on smokeless tobacco cessation for youth  805

Figure 6.1  Approaches to smoking prevention overlaid on the Theory of Triadic Influence (TTI)  634

Figure 6.2  Cigarette prices and prevalence of smoking among youth, 1975–2011  701

Figure 6.3  Map of 100% smoke-free air laws, United States, July 1, 2011  708

Figure 6.4  Synar noncompliance rate by year: average of 50 states and the District of Columbia weighted by state population  711

Figure 6.5  Health warnings on cigarette packages in the United States  716

Figure 6.6  Pictorial warning on cigarette package in Canada  717

Figure 6.7  Pictorial warning on cigarette package in Australia  718

Figure 6.8  Proposed pictorial warnings on cigarette packages in the United States  719

Chapter 7  A Vision for Ending the Tobacco Epidemic

Table 7.1  Cumulative percentages of recalled age at which respondents first tried a cigarette and began to smoke daily among 30- to 39-year-olds who have ever smoked daily, 1991 compared with 2010  851

Table 7.2  Strategic actions to end the tobacco epidemic  855

Figure 7.1  Current rates of cigarette smoking among high school students and projected rates if the 1997–2003 decline had continued; Youth Risk Behavior Survey (YRBS) 1991–2009; United States  856
A

AAP. See American Academy of Pediatrics
abdominal aorta, atherosclerosis in, 100–101
academic achievement, 161–162, 434–436
    current smoking prevalence by, 175, 233, 436
    smokeless tobacco use by, 201, 271
accessibility of tobacco
    industry-sponsored prevention programs, 555–557
    physical environment, 437–438 (See also retail outlets)
    regulations on, 710–712
acculturation, 432–433
“Action Against Access” program, 556–557
activism, youth, 789–792
ADAMHA. See Alcohol, Drug Abuse, Mental Health Administration Reorganization Act
Add Health. See National Longitudinal Study of Adolescent Health
depression. See nicotine addiction
additives, 536–537. See also flavor additives
ADHD. See attention deficit hyperactivity disorder
adolescent, definition of, 6
Adolescent Dieting Scale, 64
adult smokers. See also parental smoking; young adults
    antismoking campaigns targeting, 690
    brand-specific advertising for, 517–518
advertising, 508–522. See also marketing practices
    bans (See advertising bans)
    definition of, 712–713
    expenditures, 488–507
    cigarettes, 488–500
    smokeless tobacco, 491, 501–507
    imagery in, 508, 519
    brand packaging, 530–533, 535
    broadcast media (See movie smoking; television advertising)
    impact evaluation, validity of, 438, 514, 713–714
    in retail stores (See point-of-sale marketing)
    of smoking cessation products, 635
    summary, 487, 508–509, 851–852
    themes used in, 508, 519, 599
    types of, 488–490
    weight control emphasized in, 31, 530–532
advertising bans, 712–715
digital marketing, 547
    econometric analyses of, 514
    effectiveness of, 438, 598–599
    current evidence base, 714–715
    discussion, 715, 810–811
American Heart Association (AHA) grading system, 97–100
American Indians
  epidemiology (See racial/ethnic groups)
  religious use of tobacco, 431–433
  smokeless tobacco use, 803–804, 808
  tax exemption, 706
American Legacy Foundation
  creation of, 4, 850
  Media Tracking Surveys, 688
  social networking campaign, 688
  tobacco industry payments to, 852
  “truth” ads, 558, 561, 635, 687–690, 850
  YE (Youth Empowerment) Work Group, 789
American Lung Association (ALA), 553
American Medical Association (AMA), 694, 727
American Nonsmokers’ Rights Foundation, 707
American Psychiatric Association, 23–24
American Smokers Alliance, 550
American Snuff Company, 202, 539–540
American Stop Smoking Intervention Study for Cancer Prevention (ASSIST), 694, 696, 786
American Tobacco Company, 31, 487
Americas (PAHO), tobacco use, 209–210
  age of onset/ever smoked, 297–300, 407–408
  current prevalence, 319–322, 330–331, 409–410
  intensity of smoking, 308–311
  smoking cessation, 319–322, 411–412
ammoniated products, 536–537
Amsterdam Growth and Health Study (Netherlands), 83
animal studies
  cardiovascular effects, 96–97
  nicotine withdrawal, 456
antioxidant levels, 95–96
antitobacco policies
  antismoking campaigns (See smoking prevention)
  government-level (See tobacco control policies)
    home-based, 709–710
    school-based, 435, 707–709, 787–788
anxiety disorders, 27–28, 445–447
aortic pulse wave velocity, 108
apolipoprotein E (Apo E) knockout mice, 96
appetite control, 43, 58–59, 63. See also weight control
  “area effect” of smoking, 434
Argentina, weight control behavior, 58–59
Ariva (brand), 533
Arizona, tobacco control program, 694, 696
Asian youth. See racial/ethnic groups
ASPIRE program, 786
ASSIST. See American Stop Smoking Intervention Study for Cancer Prevention
associations, 449, 533
asthma, 87–94
  definition of, 87
  epidemiologic evidence
    cross-sectional studies, 88–91
    prospective cohort studies, 91–94
  lung growth and, 86
  summary, 94
atherosclerosis
  postmortem studies, 97–101
  subclinical, 101–102
  summary, 101
  vascular injury in, 96
attention deficit hyperactivity disorder (ADHD), 27–28
attitudes toward smoking
  affective processes, 445–447, 451
  antitobacco industry, 554–555, 558, 561, 635
  cognitive processes, 447–451, 459
  epidemiology, 191–192, 369–371
  family context, 443–445
  large social environment, 431–437
  marketing and, 509, 512, 519–522, 532–533, 544
  movie smoking and, 596–598
  peer groups, 439–443, 519–522
  in schools, 788
  smoking prevention and, 558, 561, 632–633, 686–690
  trends in, 192, 431
audience segmentation, in antismoking campaigns, 689–691
audiovisual advertising, expenditures on, 489, 501–502
Australia
  endothelial dysfunction study, 102
  health warnings, 717–718
  lung function studies, 86
  marketing practices, 511, 513, 517, 531, 533, 535, 548
  school tobacco policies, 788
  smoking prevention programs, 558, 690, 692, 721
  weight control behavior, 64
automatic cognitive processes, 448–451
awareness of smoking, 511–512

B

Bacall, Lauren, 565
Backwoods (brand), 283–284, 286
Balanced Budget Act (1997), 698
Barker, David, 21
Barker hypothesis, 21
bars, promotional activities in, 522, 534
Basic, 366–367
BAT. See British American Tobacco
B&W. See Brown & Williamson
Beach method, 571, 574
Beech-Nut, 274, 278
behavioral risk factors
  health-related, 194–197, 372–381, 633
  marketing influences, 509, 512–513, 599
  mental health issues, 27–28
  tobacco use, 427–429 (See also etiology of tobacco use; smoking behavior)
  smoking prevention based on, 631–632, 636–637, 809
Behavioral Risk Factor Surveillance System (BRFSS), 201, 697, 703
“below the line” marketing activities, 534
Bernays, Edward L., 565
BE smokeFREE program, 721, 726
Best Practices for Comprehensive Tobacco Control Programs
Guide (CDC), 711, 809, 853
BHR. See bronchial hyperresponsiveness
bias, in advertising impact studies, 713–714
bidis
measures of use, 217, 423
prevalence of use, 206–207, 288, 400–401
billboard advertising
antismoking messages, 688
tobacco industry expenditures on
cigarettes, 489, 491–493
smokeless tobacco, 501–502
biological risk factors, 428
bipolar disorder, 27
birth weight, 96, 108
Black & Mild (brand), 164, 205, 282, 285, 539
blood pressure, 97, 199
blunts, 205–206, 287
BMI. See body mass index
body image, 44–45, 57, 64–65, 68
body mass index (BMI), 44, 70–75
body weight, 69–79
after initiation of smoking, 75–79
after smoking cessation, 59, 69, 75–77
control of (See weight control)
low birth weight, 96, 108
of smokers, 69–75
Bogalusa Heart Study, 100–102, 108–109
Bogart, Humphrey, 565
bogus pipeline, 215
Bonsack, James, 487
bonus products, expenditures on, 490–492, 494, 502–503
book covers, smoking prevention campaign using, 554
Boys & Girls Clubs of America, 555, 692
brachial artery, vascular reactivity in, 102, 108
brain development, 428, 451, 455–459
brand(s). See also specific brand
developers, 31, 530–532, 697
development of (See also product design)
expenditures on, 488
discount, 523–526, 547
loyalty to, 516, 518–519
marketing specific to, 161–164, 177, 507, 516–522
packaging of, 530–531 (See also packaging)
recognition of, 511–512, 516
brand ambassadors, 546, 552
branded merchandise, expenditures on
cigarettes, 490–493, 497–500
smokeless tobacco, 501, 505–506
branded products, in movies, 566–567
brand preferences
changes in, 516–518
cigars, 164, 205, 282–286
definitions of, 216–217, 418, 421, 423
packaging and, 530–531
smokeless tobacco, 164, 201–202, 273–275, 277–278
Brazil, health warnings, 719
Breathe California-Sacramento Emigrant Trails, 569
breathlessness, 88–94
BRFSS. See Behavioral Risk Factor Surveillance System
British American Tobacco (BAT), 528, 534
broadcast advertising. See mass media advertising
bronchial hyperresponsiveness (BHR), 88, 94
bronchitis, 88–94
Brown & Williamson (B&W). See also Reynolds American, Inc.
digital marketing, 546
Kool brand (See Kool)
marketing expenditures, 488
product design, 537–538
smoking prevention program, 554–555
Brundtland, Gro Harlem, 857
built environment, 437–438
bulimia, 60–64
bupropion, 800
Busselton Health Study, 726

C

CAI. See computer-assisted interviewing
California, tobacco control program, 694, 696, 853
Camel (brand)
ad campaigns, 515–516
brand-specific marketing, 516, 518–519, 521
Camel Crush, 537–538
Camel Snus, 274, 278, 507, 540, 549
dissolvables, 507, 540
flavor additives, 538–539
image advertising, 519
Joe Camel persona, 511–512, 516, 518–519, 521, 537, 849
market share, 161–164, 177–178, 190, 239–242, 366–367, 507, 850
price promotions, 491, 528–529
product design, 535–537
Web site, 546, 548
youth-directed advertising, 519
Canada
academic achievement studies, 161
health warnings, 716–717, 719
marketing practices, 531–534, 543–545
school-based programs, 788, 791
socioeconomic factors, 434
weight control behavior, 57
cancer
epidemiology, 188
smokeless tobacco-related, 199, 806, 808
candidate gene studies, 452
candy flavoring, See flavor additives
Capri (brand), 31
Captain Black (brand), 540
carbonates, 536
carbowax, 537
CARDIA. See Coronary Artery Risk Development in Young Adults
cardiovascular consequences, 94–109
atherosclerosis, 97–102
endothelial dysfunction, 102–108
evidence review methods, 96
insulin resistance, 109
lipids, 108–109
physiological effects, 97
prenatal exposure, 94
smokeless tobacco use, 199
summary, 109
vascular injury, 95–96
Cardiovascular Risk in Young Finns study, 101–102
Carolina Population Center (UNC-Chapel Hill), 212
carotid arteries, atherosclerosis in, 101–102
Caufield, R.T., 521
causal criteria, 7–8
causation, levels of, 631–632. See also etiology of tobacco use
CDC. See Centers for Disease Control and Prevention
Center for Substance Abuse Prevention (CSAP), 720
Centers for Disease Control and Prevention (CDC), 7
Behavioral Risk Factor Surveillance System (BRFSS), 201, 697, 703
Best Practices for Comprehensive Tobacco Control Programs Guide, 711, 809, 853
Global Tobacco Surveillance System (GTSS), 156, 209–210
IMPACT program, 694, 696
Media Campaign Resource Center, 636
movie smoking analyses, 569, 598
National Center for Health Statistics, 212
National Tobacco Control Program, 694, 696
school-based program recommendations, 732
School Health Policies and Programs Study, 707
tobacco control funding recommendations, 695–696
central processing systems, in communication theory, 636
cessation
smokeless tobacco use, 804–808
smoking (See smoking cessation)
Changing Adolescent Smoking Prevalence (NCI Monograph 14), 5
checkout counter, advertising positioned by, 543–544
Chesterfield (brand), 31
Chewer's Choice program, 807
chewing tobacco. See smokeless tobacco
Chilcote, Samuel D., Jr., 555
children
awareness of smoking, 511–512
definition of, 6
weight control beliefs, 32–43
Chile, respiratory disease, 88
China
 cultural influences on smoking, 433
 endothelial dysfunction study, 102
 cholesterol, 108–109
 cholinergic nicotinic subunit receptor genes (CHRNA5/A3/B4), 26
chronic obstructive pulmonary disease (COPD), 80, 86, 88
cigars
definition of, 203
digital marketing of, 549
flavored, 155, 205
online sales of, 547
pricing, 155, 706
taxes on, 698
cigar smoking
brand preferences, 164, 205, 282–286
disparities, 154
etiology of, 430
ever used, 203, 279
genetic factors, 454
measures of, 217, 421–423
substance use comorbidity, 287
trend data, 149–151, 195, 205, 294, 399
Citi Investment Research, 533
clean air policies, 707–710
home-based, 709–710
impact on tobacco use, 708–709
school-based, 435, 707–709, 787–788
smokeless tobacco products and, 541, 549, 551
social norms created by, 437
state-level, 697
summary, 710, 810
Clean Indoor Air Act (2003), 697
clinical interventions, 727–731
barriers to, 730–731
delivery rates, 728–729
guidelines, 727–728, 731
research support, 729–730
smokeless tobacco use, 802, 807
smoking cessation, 799–801
summary, 731
theories underlying, 633–634
clinical studies, weight control behavior, 60–63
clove cigars, 155, 205
clove cigarettes (kretes)
 measures of use, 217, 423–424
prevalence of use, 206–207, 288, 402–403
cocaine use
prevalence of, 195, 373
tobacco use risk, 28–29
Cochrane reviews, 5
marketing practices, 516–517
smoking prevention, 683, 692
cessation programs, 793
family interventions, 720–727
school-based programs, 732–734
youth access, 711–712, 810
cognitive processes, 447–451, 459
  neurodevelopmental, 451, 456–459
  smoking prevention and, 632–633
coherence of association, 7
Cohiba (brand), 283, 286
color of packaging, 530, 532–533
COMMIT. See Community Intervention Trial for Smoking Cessation
Commonwealth Brands, Inc., 488
communication theories, 636–637, 686
Communities that Care (CTC) program, 786
community interventions, 692–693
  evaluation methods, 634
  evidence summary, 811
  industry-sponsored, 555
  mass media (See mass media antismoking campaigns)
  smokeless tobacco use, 802–803, 806
  youth empowerment and activism, 789–792
Community Intervention Trial for Smoking Cessation (COMMIT), 693
Community Preventive Services Task Force, 5, 712, 810
computer-assisted interviewing (CAI), 131, 213
conclusions
  major, 8
  epidemiology, 9, 165
  etiology of tobacco use, 10, 460
  health consequences, 9, 111
  from previous Surgeon General’s Reports, 4, 15–21
  tobacco industry practices, 10, 601–602
  tobacco use prevention, 10, 812
condom use, 195, 375
conduct disorders, 27–28
consistency of association, 7
contemplation stage, 430
content analysis, movie smoking, 566, 571–574
controlled cognitive factors, 447–448, 450–451
controlled-exposure studies, 558–563, 637–646, 683–688
convenience stores, 543–544
Conwood Tobacco Company (American Snuff Company), 202, 539–540
COPD. See chronic obstructive pulmonary disease
Copenhagen (brand)
  market share, 201–202, 273, 275, 277
  packaging, 531
  product design, 540
  Web site, 548
coping theories, 447–448
copy-test studies, 686–687
coronary arteries, atherosclerosis in, 100–101
Coronary Artery Risk Development in Young Adults (CARDIA) study, 75, 83, 97, 101–102, 109
cotinine levels, 108, 710
cough, 88–94
counseling. See clinical interventions
counter displays, 543–544
coupons. See price promotions
credit card payments, for online tobacco sales, 548
cross-promotion arrangements, tobacco/movie industry, 565
“crush” concept, 537–538
CSAP. See Center for Substance Abuse Prevention
CTC. See Communities that Care
cultural-environmental stream, 509–511, 599, 632–634
cultural influences, 432–433, 509
  family interventions, 726–727
  school-based programs, 787
Current Population Surveys, 709
  Tobacco Use Supplement to the, 177, 435, 705, 707–708
current smoking
definition of, 216, 415, 419–424
prevalence of (See epidemiology)
curriculum interventions, 802–803
D

Danieles, Draper, 518
D.A.R.E. (Drug Abuse Resistance Education) program, 725, 732, 788–789
D.A.R.E. Plus (Play and Learn Under Supervision) program, 725, 727
data analysis, 134
data collection methods, 215–217, 713–714
data sources, 131–133, 210–214
defective advertising, brand descriptors as, 531–532
deep sequencing, 453
deliberate processing of information, 447–448
demand, price elasticity of, 699–706
depressive disorders, 27–28
  affective processes, 445–447
  epidemiology, 198, 266
  suicidal ideation, 195–196, 376
descriptors, brand, 31, 530–532, 697
desire to smoke, influence of advertising on, 512, 532–533
developmental disorders, 27–28
developmental patterns of smoking, 429–430
  epidemiology, 179–185, 245–248
  genetic influences, 25–26, 456–457
  marketing influences, 515–516
  developmental risk factors, 428–429
  neurobiological, 451, 455–459
  smoking prevention based on, 632–633
DHL, 548
diabetes, 109
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 23–24
diammonium phosphate, 536–537
diet, 196, 379–380
dieting
  initiation of smoking and, 64–65, 68
  smoking behavior and, 44–45, 57–60
Digianni, John, 530
digital marketing, 546–552
  bans on, 547
  cessation programs, 800–801, 807
cigars, 549
Expenditures on, 490, 493–494, 502–503, 546
direct mail advertising
  expenditures on, 490, 492, 494, 501–502
  increased use of, 508
discount brands, 523–526, 547
discussions. See price promotions
Disney, 570
disruptive disorders, 27–28
dissolvable products, 155, 507, 540, 548
distal factors, 509–511, 632–633
Djarum (brand), 205
dopamine pathway, 455
  candidate genes, 26, 452
drug use. See substance use; specific drug
DSM-IV-TR. See Diagnostic and Statistical Manual of Mental Disorders
Duke, James Buchanan, 487
Dutch Masters (brand), 205, 282, 284–285
dynamic system, behavior as, 632
dyslipidemia, 108–109
dyspnea (shortness of breath), 88–94

E
eastern Mediterranean (EMRO), tobacco use, 209–210
  age of onset/ever smoked, 300–301, 407–408
  current prevalence, 322–323, 332–333, 409–410
  intensity of smoking, 311–312
  smoking cessation, 322–323, 411–412
eating disorders
  initiation of smoking and, 68
  smoking behavior and, 45, 56, 60–64
Eating Disorders Inventory (EDI), 57, 63–64, 68
eating habits, 196
  econometric studies
  marketing-smoking link, 513–514
  price-smoking link, 699–706
EDI. See Eating Disorders Inventory
educational levels
  academic achievement (See academic achievement)
  current smoking prevalence, 175, 177, 233, 436
  smokeless tobacco use, 200–201, 271
  smoking trend data, 189–190
  tobacco use disparities, 153–154
effect modification, 592
Eight Men Out (movie), 566
elaboration likelihood model of persuasion, 636
electronic cigarettes (E-cigarettes), 155, 549–551
electronic technology
  advertising (See digital marketing)
  cessation programs using, 800–801, 807
  emotional response, to antismoking messages, 636, 686–689, 718, 810
emphysema, 88
employment levels. See socioeconomic status
empowerment, youth, 789–792
EMRO. See Eastern Mediterranean
Ending the Tobacco Problem: A Blueprint for the Nation (IOM), 4
Ending the Tobacco Problem: A Tobacco Control Strategic Action Plan (USDHHS), 854–856
endogeneity, 714
endorsements, expenditures on, 490, 501, 503
endothelial dysfunction, 102–108
entertainment media. See movie smoking; television advertising
environmental factors
  evidence summary, 458–459
  genetic interaction with, 454–455
  large environment
    physical, 437–439, 458
    social, 431–439, 458
  marketing and, 509
  protective, 631
  retail stores, 541 (See also point-of-sale marketing)
  small social groups, 439–445, 458–459
  smoking prevention based on, 631–634
  summary, 427–429
environmental stream, 632–634
environmental tobacco smoke. See clean air policies; secondhand smoke
epidemiology
  academic achievement, 161–162, 434–436
cigarette smoking
  age at onset, 134–136, 164, 179–180, 190–191, 238, 244, 295–305
  developmental patterns, 179–185, 245–248, 344
  disparities in, 149–154
  expectations to smoke, 183–184, 249–251
  initiation of smoking, 142–143, 179–180, 261
  knowledge and attitudes about, 191–192, 368–371
  measures of, 215, 415–419
Preventing Tobacco Use Among Youth and Young Adults

depression, 198, 266

evidence summary, 164–165

factors

gender (See gender)
racial/ethnic (See racial/ethnic groups)
socioeconomic (See socioeconomic status)
U.S. regional (See United States regional variations)
health-related behaviors, 194–197, 372–381
international statistics (See worldwide tobacco use)
key measures, 133–134
lung cancer, 188
nicotine addiction, 184–185, 252–256
recent trends, 850–852
smokeless tobacco use
age at onset, 201, 272, 291–293
brand preferences, 164, 201–202, 273–275, 277–278
current prevalence, 142, 144, 146, 164, 200–201, 269–271, 374, 382–388
disparities, 154
ever used, 199–200, 267–268, 392
measures of, 216–217, 419–421
prices, 202, 706
substance use comorbidity, 193–194, 203
trend data, 144–149, 195, 202, 293–294, 389–392
specific use (bidis & kreteks)
measures of use, 217, 423–424
prevalence of use, 206–207, 288, 400–403
substance use, 193–195, 203, 205–206
suicidal ideation, 193–197, 376
tobacco use measures, 215–217, 415–424
violence, 193–197, 376–377

ESPAD. See European School Survey Project on Alcohol and Other Drugs

estimation equation, specification of, 713

ethanolamines, 536
ethnic groups. See racial/ethnic groups
etiology of tobacco use
affective processes, 445–447, 451
cognitive processes, 447–451
conclusions, 10, 460
developmental stages, 429–430
evidence summary, 458–460
genetics (See genetic factors)
large environment
physical, 437–439
social, 431–439
multilevel influences, 459
neurobiological processes, 455–458
other forms of tobacco than cigarettes, 430
prenatal exposure, 457
small social groups
family, 443–445
peers, 439–443
smoking prevention theories based on, 631–632
summary, 427–429, 850–851

Eunice Kennedy Shriver National Institute of Child Health and Human Development, 212

EURO. See Europe (EURO) region

European School Survey Project on Alcohol and Other Drugs (ESPAD), 210, 337–338

Europe (EURO) region
marketing practices, 531–532
tobacco use, 209–210, 337–338
age of onset/ever smoked, 301–303, 407–408
current prevalence, 323–325, 333–334, 409–410
intensity of smoking, 312–314
smoking cessation, 323–325, 411–412

ever used
cigars, 203, 279
definitions of, 216–217, 415, 419, 421, 423
smokeless tobacco, 199–200, 267–268, 392

evidence review methods, 7–8
evidence summary
environmental factors, 458–459
epidemiology, 164–165
etiology of tobacco use, 458–460
health consequences, 110
marketing practices, 598–601
tobacco use prevention, 809–811

executive function, 448
exemplars, in antismoking strategy, 637
exercise, 196, 379
expectancy, 447
expectations to smoke, 183–184, 249–251
cognitive and affective processes, 446–447
experimentation stage, 430. See also initiation of smoking
explicit cognitive factors, 447–448, 450–451
extracurricular activities, 437, 455
Facebook, 549–551, 688
Fagerström Test for Nicotine Dependence (FTND), 23–24, 454
Fagerström Tolerance Questionnaire (FTQ), 23, 181
modified for adolescents (mFTQ), 24
Fairness Doctrine, 635, 684, 691
family. See also parental behavior
gene-environment interaction, 454–455
influence of, 443–445, 631
Family C.O.U.R.S.E. Consortium, 553
family interventions, 720–727
effectiveness of, 720–727
ineffective programs, 726
recommendations, 727
study limitations, 726–727
systematic reviews, 720–726
self-help booklets, 552–553
smoking cessation, 799–800
types of, 720
Family Matters program, 725–726
Family-School Partnership program, 721
Family Smoking Prevention and Tobacco Control Act (2009), 697
advertising bans, 600
brand descriptors, 697
FDA authority established by, 4, 545, 810, 854
health warnings, 719, 810
online tobacco sales/marketing, 548
product design and packaging, 205, 531, 534, 539, 541
specialty cigarettes (bidis and kreteks), 207
youth access, 810
FCP. See Full Court Press
FCTC. See Framework Convention on Tobacco Control
FDA. See U.S. Food and Drug Administration
Federal Communications Commission (FCC), 547, 635, 684
federal taxes, 698–699. See also taxation
Federal Trade Commission (FTC)
marketing activities reported to, 488–494, 501–503, 507, 546, 715
movie imagery investigation, 565
FedEx, 548
females
advertising aimed at, 31, 519, 530–533
epidemiology (See gender)
increase in tobacco use by, 156
smoking during pregnancy, 457 (See also prenatal exposure)
Surgeon General’s Report (2001) on, 4
fetus
DNA damage in, 21–22
lipid levels in, 109
low birth weight, 96, 108
neurodevelopmental processes, 457, 459
vascular injury in, 96–97
films. See movie smoking
filter ventilation, 531, 536–537
financial incentives for retailers. See product placement
Finland
cardiovascular risk study, 101–102, 108
family interventions, 721
socioeconomic factors, 434
Fire Safety Standards for Cigarettes Act (2004), 697
First Amendment protection, 564
first use. See initiation of smoking
“5 As” model, 728, 731
flavor additives
in cigarettes, 537–539
in electronic cigarettes, 549
FDA ban on, 164, 178, 205, 207, 539
menthol as, 178, 539
in smokeless tobacco products, 539, 549
flavored cigars, 155, 205
Florida, tobacco control program, 694, 849, 853
Focus on Kids (FOK) program, 725
Food, Drug, and Cosmetic Act, 853
Food and Drug Administration. See U.S. Food and Drug Administration
Foote, Emerson, 517–518
forced-exposure studies, 558–563
4-H program, 555, 805
Framework Convention on Tobacco Control (FCTC), 531, 545, 719
France, respiratory disease, 91
free nicotine levels, 539–541
frequency of smoking. See intensity of smoking
friends. See peer groups
fruit flavoring. See flavor additives
FTC. See Federal Trade Commission
FTND. See Fagerström Test for Nicotine Dependence
FTQ. See Fagerström Tolerance Questionnaire
Full Court Press (FCP), 693
GABA (gamma amino butyric acid) pathway, 455
GABA (gamma amino butyric acid) receptor genes, 452
Garcia y Vega (brand), 283, 286
gateway drug, tobacco as, 28–29, 193–194
gender. See also females; males
advertising campaigns, 519
antismoking campaigns, 690
cigarette smoking
age of onset, 191, 295–305
brand preferences, 163, 177–178, 239–242, 366–367, 536
cultural influences, 433
trends in, 187–189, 433
disparities, 149, 152
ever smoked, 173, 185–186, 227–228, 345–346, 349, 407–408
intensity of smoking, 175, 234–237
knowledge and attitudes, 192, 370
nicotine dependence, 184–185, 252–255
substance use comorbidity, 193, 263
susceptibility to smoking, 179, 243, 295–305
trajectories of smoking, 181–182, 245–248
trend data, 139–141, 143, 185–191, 257–261, 294, 345–346, 349
cigar smoking
brand preferences, 205, 282–283, 285–286
ever used, 203, 279
trend data, 399
clinical interventions, 728
depression, 198, 266
family interventions, 726–727
lung cancer rates, 188
lung growth patterns, 80–85
movie smoking and, 569
peer group influences, 439
smokeless tobacco use
age of onset, 291–293
brand preferences, 273–274, 277–278
current prevalence, 142, 144–149, 164, 200–202, 269–270, 382–390
ever used, 199, 267–268
prevention programs, 802–804
prices, 706
social norms, 433, 438
specialty cigarettes (bidis & kreteks), 206–207, 288, 400–403
water pipes (hookahs), 206
weight control
beliefs about, 32–45
epidemiologic findings, 157–161, 197
initiation of smoking, 63–68
smoking behavior, 45–60
smoking cessation, 69, 75
worldwide tobacco use, 156, 158–159, 165, 209–210
age of onset/ever smoked, 295–305
current prevalence, 317–336, 409–410, 433
intensity of smoking, 306–316
smoking cessation, 317–327, 411–412
gene-wide association studies (GWAS), 452–453
genomic sequencing, 453
Germany
chronic respiratory disease, 91
marketing influences, 511
movie smoking, 575, 591, 598
gingival recession, 199
Global Adult Tobacco Survey, 210
Global Health Professionals Students Survey, 210
Global School Personnel Survey, 210
Global Tobacco Surveillance System (GTSS), 156, 209–210
Global Youth Tobacco Survey (GYTS)
overview and methods, 131–133, 156, 209–211
age of onset, 295–305
ever smoked, 295–305, 407–408
intensity of smoking, 306–316
other forms of tobacco than cigarettes, 413–414
smoking cessation, 317–327, 411–412
susceptibility to smoking, 295–305
tobacco use measures, 216
glucose intolerance, 109
Goldbrenner, Ronald S., 518
Good Behavior Game program, 791
Google, 550
graduation strategy, 539–540
Grizzly (brand)
market share, 164, 201–202, 273, 275, 277
product design, 540
gross rating points (GRPs), 684
Growing Up Tobacco Free: Preventing Nicotine Addiction in Children and Youths (IOM), 4
growth mixture modeling, 180
GTSS. See Global Tobacco Surveillance System
Guiding Good Choices program, 725
GWAS. See genomewide association studies
GYTS. See Global Youth Tobacco Survey

H

halitosis, 199
Handbooks of Cancer Prevention in Tobacco Control Volume 14 (IARC), 699
haplotypes, 452
Happy Days (brand), 540
Harley-Davidson USA, 518
Harvard School of Public Health College Alcohol Study, 709
HDL. See high-density lipoprotein
Health Belief Model, 636
health care providers. See clinical interventions
health consequences. See also specific disease or symptom
antismoking campaigns emphasizing, 635, 686–688
cardiovascular (See cardiovascular consequences)
conclusions, 9, 111
from previous Surgeon General’s Reports, 4, 15–21
duration of smoking and, 22, 83
evidence summary, 110
knowledge of (See knowledge of health consequences)
nicotine addiction, 23–29 (See also nicotine addiction)
respiratory (See respiratory consequences)
smokeless tobacco use, 199, 427–428, 806, 808
summary, 15
warning labels (See health warnings)
water pipes (hookahs), 207
health-related behaviors, 194–197, 372–381, 633
“Health Rocks” program, 555
health warnings, 715–719
advertising bans and, 514
impact of
current text-based style, 715–716
“new” and rotating messages, 718
 pictorial style, 717–719, 810
recommendations, 718–719, 810
by size and position, 716–717
packaging strategies and, 532, 535
requirements, 810
variations in, 715–716
Healthy People 2010 (USDHHS), 5, 711
Healthy People 2020 (USDHHS), 5, 135, 185, 854
heart, physiological effects on, 97
Heaviness of Smoking Index (HSI), 454
Helping Youth Decide booklet, 552–553
herd brands, 521–522
heritability. See genetic factors
heterogeneity, 713–714
Heuristic-Systematic Model, 636
high-density lipoprotein (HDL) cholesterol, 108–109
high-risk youth, antismoking campaigns for, 690–691
Hispanic youth. See racial/ethnic groups
Hoelter, Timothy K., 518
home smoking policies, 709–710
HONC. See Hooked on Nicotine Checklist
Hong Kong, health consequences, 88, 102
hookahs (water pipes), 155, 206–207, 430
Hooked on Nicotine Checklist (HONC), 24, 456
household-based sampling, 131, 215
House of Menthol (Web site), 546
heart, clean air policies, 710
HSI. See Heaviness of Smoking Index
humectants, 537
Hungary, atherosclerosis, 100–101
Hutchinson Smoking Prevention Project, 733, 789
hypertension, 97, 199
hypothesis testing, 8
hypothesized endogenous variables, 592–593
Hystar, 537

I

IARC. See International Agency for Research on Cancer
IAT. See Implicit Association Test
Iceland, marketing practices, 534, 545
ICVs. See Internet cigarette vendors
identity-based peer groups, 441–443
identity development, 564, 632–633
illicit drugs. See substance use; specific drug
imagery, 508, 519
on brand packaging, 530–533, 535
in entertainment media (See movie smoking; television advertising)
IMBC. See Integrated Model of Behavior Change
immigrants, cultural influences, 432–433
ImPACT. See Informed Parents and Children Together
IMPACT. See Initiatives to Mobilize for the Prevention and Control of Tobacco Use
Implicit Association Test (IAT), 449
implicit cognitive processes, 448–451
incentives for retailers. See product placement
income. See socioeconomic status
India
family interventions, 721
movie smoking, 596
school-based programs, 786
tobacco use, 156, 433, 457
individual heterogeneity, 713–714
indoor air. See clean air policies
inflammatory markers, 96
informational approaches, 731
Informed Parents and Children Together (ImPACT) program, 725
inhalants, 193–194, 263, 276, 287
initiation of smoking
age at (See age at onset)
current trends, 850
definitions of, 216–217, 417–418, 420, 422, 429
development of addiction from, 24–27, 429–430
epidemiology, 179–185, 245–248, 344
epidemiology, 142–143, 179–180, 261
geneic factors, 25–26, 456–457
twin studies, 453–454
marketing influences, 508, 512, 515–517, 599
packaging, 533
point-of-sale advertising, 544
pricing, 529, 704–705
product design, 535–539
mental health issues related to, 27–28
movie smoking and, 575, 590–591
multiple tobacco product use, 208–209
peer group influences, 439
prevention of (See smoking prevention)
Preventing Tobacco Use Among Youth and Young Adults

risk factors for, 427–429, 632 (See also etiology of tobacco use)
stage model, 429–430
substance use risk, 29
trend data, 142–143, 261, 294
as weight control behavior, 63–68, 75–79
Initiatives to Mobilize for the Prevention and Control of Tobacco Use (IMPACT) program, 694, 696
“inserts” (package), 534
Institute of Medicine (IOM), 4, 695, 719, 785
insulin resistance, 109
integrated biopsychosocial-ecological models, 428, 631
Integrated Model of Behavior Change (IMBC), 636
intensity of smoking
definitions of, 216, 416–417
epidemiology, 175–177, 180–181, 190, 234–237
trend data, 365
worldwide statistics, 306–316
expectations to smoke and, 183–184, 249–251
genetic factors, 453–454
health consequences, 22, 83, 85
nicotine addiction and, 184, 429–430
pricing and, 702–704, 706
weight control beliefs, 42–43, 65–66
intentions to smoke
behavior linked to, 509, 512
marketing influences on, 512–513, 520, 543
movie smoking and, 596–598
smoking prevention programs and, 561, 687–689
interaction-based peer groups, 441–443
Interactive, Inc., 554
International Agency for Research on Cancer (IARC), 699
International Study of Asthma and Allergies in Childhood (ISAAC), 88, 91
international tobacco use. See worldwide tobacco use; specific region or country
Internet advertising. See digital marketing
Internet-assisted cessation programs, 800–801, 807
Internet cigarette vendors (ICVs), 547–548
intrapersonal factors, 428–429, 459, 509, 599
intrapersonal stream, 632–634
involuntary smoking. See secondhand smoke
IOM. See Institute of Medicine
Iowa Strengthening Families Program (ISFP), 725–726
Ireland
marketing practices, 545
respiratory disease, 88
weight control behavior, 57
ISAAC. See International Study of Asthma and Allergies in Childhood
ISFP. See Iowa Strengthening Families Program
Israel, respiratory disease, 91
“It’s the Law” program, 555–557

J

Japan, endothelial dysfunction, 102, 108
Japan Tobacco, 538
John Middleton Co., 539
Johnston, Myron, 527

K

Kessler, David, 849
Kessler, Gladys, 508, 521–522
Kickbutts program, 726
kinky oligopoly, 523
knowledge of health consequences
cognitive processes, 448
epidemiology, 191–192, 368, 392
health warnings and, 715–719
packaging and, 531–532
as risk factor, 427–428
smokeless tobacco use, 428, 806, 808
Kodiak (brand), 274–275, 277, 540
Kool (brand)
digital marketing, 546
market share, 366–367, 537
product design, 536, 538
Korea, weight control behavior, 59–60
kreteks
measures of use, 217, 423–424
prevalence of use, 206–207, 288, 402–403

L

labeling
brand descriptors, 31, 530–532, 697
public health (See health warnings)
large environment
physical, 437–438, 458
social, 431–437, 458
latent class analysis (LCA), 182
latent transition analysis (LTA), 182
LCA. See latent class analysis
LDL. See low-density lipoprotein
learning, cognitive-behavioral principles of, 447–448
LeBow, Bennett S., 518
left ventricular mass, 97
legislation. See regulation; specific law
Leo Burnett, 520
leukoplakia, 199
Levi Garrett, 273, 275, 278
LifeSkills Training (LST) program, 554–555, 725–726, 785, 791
Liggett Group, LLC, 488, 518, 566
“light” descriptors, 531–532, 697
lingering effects, of advertising, 713
linkage analyses (genetic), 451–452
lipids, 108–109
literacy skills, health warnings and, 718–719
local governments
  clean air policies, 707–710
taxes, 699 (See also taxation)
youth access laws, 710–712, 810
logos, on packaging, 530, 532–533
Longhorn, 275
Lorillard Tobacco Company, 488, 518–519
brand-specific advertising, 507
Newport brand (See Newport)
smoking prevention programs, 553, 557, 635
low birth weight, 96, 108
low-density lipoprotein (LDL) cholesterol, 109
low-income neighborhoods. See also socioeconomic status
tobacco marketing in, 542–543
“low tar” descriptors, 531–532, 697
LST. See LifeSkills Training
LTA. See latent transition analysis
Lucky Strike (brand), 31, 565–566
Lund, Nancy B., 520
lung cancer, 188
lung function, 80–86
gender patterns, 80–85
intensity of smoking, 83, 85
summary, 86–87

magazine advertising, expenditures on
cigarettes, 489, 491–493
smokeless tobacco, 501–502
maillard browning process, 535
males
advertising aimed at, 519
epidemiology (See gender)
marijuana use
nicotine addiction and, 184–185, 252–255
prevalence of, 194–195, 373
tobacco use risk, 28–29
marketing practices
advertising (See advertising)
brand-specific, 161–164, 177, 507, 516–521
conceptual framework, 509–511
conclusions, 10, 601–602
definition of, 713
entertainment media (See movie smoking; television advertising)
evidence summary, 598–601
expenditures on, 488–507, 541, 546, 715, 852
cigarettes, 488–500
smokeless tobacco, 491, 501–507
impact of, 438, 487, 508–509, 599
awareness of smoking, 511–512
brand preferences, 516
initiation of smoking, 508, 512, 515–517, 529, 533, 535–539, 544
intentions to smoke, 512–513, 520, 543
peer pressure, 519–522
smoking behavior, 513–517, 520
systematic reviews, 516–517
Internet (See digital marketing)
packaging (See packaging)
point-of-sale (See point-of-sale marketing)
prices (See pricing)
product design, 535–541
promotions (See promotional activities)
regulation of (See advertising bans)
summary, 487, 508–509, 851–852
tobacco industry position on, 517–522
types of, 488–491
women as target of, 31, 519, 530–533
young adults as target of, 508, 518–522
market-level data, validity of, 713
Marlboro (brand)
brand-specific marketing, 516, 518–521
market share, 161–164, 177–178, 190, 239–242, 366–367, 507, 850
Marlboro Man persona, 511–512, 518
Marlboro Snus, 507
point-of-sale advertising, 529
price promotions (“Marlboro Friday”), 488, 523–525
product design, 535–537
retail-value-added promotions, 491
Web site, 546, 548
masking agents, 535–539
Massachusetts, tobacco control program, 694, 849
Massachusetts Prevalence Study, 802
mass media advertising. See also movie smoking; television advertising
ban on, 507, 566, 574, 635
econometric analyses of, 514
mass media antismoking campaigns, 635–692
audience segmentation, 689–691
content and formats, 686–688
context, 689
effectiveness of, 637–686
controlled exposure studies, 558–563, 637–646, 683–684
naturalistic exposure studies, 558, 561–562, 669–682, 686–688
population-based studies, 647–668, 684–686
history of, 635
industry-sponsored, 557–563, 635, 687
intensity and duration, 688–689

886
optimizing factors, 686–691
review methodology, 636–637
summary, 691–692, 809
theoretical implications, 691
theories underlying, 633–634, 636–637
“truth” ads, 558, 561, 635, 687–690, 850
Master Settlement Agreement (1998), 4, 850
advertising bans, 437, 487, 714–715, 810
entertainment media imagery since, 564
marketing expenditures since, 488–491, 507–508
movie imagery since, 566–567
non-participating manufacturers (NPMs), 525–526
original participating manufacturers (OPMs), 525–526
point-of-sale marketing since, 541–544, 600
pricing since, 513–514, 525–528, 530
product design since, 538
Smokeless Tobacco, 507
smoking trends since, 139–141, 185, 191, 515–516, 852
subsequent participating manufacturers (SPMs), 525–526
taxes and, 699
tobacco control funding, 554, 694, 852–853
maternal smoking. See parental smoking; prenatal exposure
Maxwell Report, 275, 284
McCann-Erickson, 517
measurement error, 713
measures of tobacco use, 215–217, 415–424
Media Campaign Resource Center (CDC), 636
mediational pathways, 592–593
medical settings. See clinical interventions
memory associations, 449
Memory Association Test, 449
Memphis Health Project, 32, 56, 65, 68
mental health, 27–28
mentholated cigarettes, 537–539. See also specific brand
brand preferences, 161, 177–178, 190, 537
cultural influences on use of, 432, 543
effect on lung function, 83–86
as flavoring, 178, 207, 339
initiation of smoking with, 535, 538–539
product design, 537
use by young smokers, 538–539
Merlo, Ellen, 554
mesocorticolimbic dopamine system, 455
metropolitan statistical areas (MSAs)
current smoking prevalence, 175, 233, 271
smokeless tobacco use, 201
Mississippi, tobacco control program, 694, 849, 853
mobile telephones, cessation programs using, 801, 807
moderate-to-vigorous physical activity (MVPA), 196
moderation effects, 592
moist snuff. See smokeless tobacco
Monitoring the Future (MTF): A Continuing Study of American Youth
overview and methods, 131–133, 211–212
academic achievement, 161–162
cigarette smoking
current prevalence, 174–175, 187–189, 229–230, 233
expectations to smoke, 183–184, 249–251
initiation of smoking, 180, 244, 704
intensity of smoking, 175–177, 190, 236–237, 365
intentions to smoke, 512–513
prices, 702, 704–706
smoking cessation, 368
substance use comorbidity, 193, 263–264, 276, 371
trend data, 138–142, 164, 185–191, 257, 345–353
cigar smoking, 149
clean air policies, 709
marketing exposure, 529, 561
movie smoking, 567–569
multiple tobacco product use, 207–209, 262, 276, 289–290
perceived health risks, 191–192, 368, 392
perceptions of smoking, 192, 369–371
school tobacco policies, 788
smokeless tobacco use
age at onset, 201, 291
ever used, 199–200, 267–268
substance use comorbidity, 203, 276, 371
substance use comorbidity, 193, 263–264, 276, 371
tobacco control funding, 696
tobacco use disparities, 149, 153
tobacco use measures, 216–217, 415–424
mood, 445–447
Motion Picture Association of America (MPAA), 570, 598
motivational approaches, 731
Mountain Dew (brand), 548
movie smoking, 565–598
content analysis, 566, 571–574
depictions of smoking, 567–570
as environmental factor, 437–438
experimental research, 596–598
exposure assessment, 571–574
historical links between tobacco industry and, 565–566
identity development and, 564
media company responses, 570–571
movie ratings, 564, 569–571, 574, 593–596, 598
movie stars as role models, 564, 571, 597
movie trailers, 571
population-based research, 575–596
cross-sectional studies, 575, 593
longitudinal studies, 575–592
mediation pathways, 592–593

Mississippi, tobacco control program, 694, 849, 853
mobile telephones, cessation programs using, 801, 807
moderate-to-vigorous physical activity (MVPA), 196
moderation effects, 592
moist snuff. See smokeless tobacco
Monitoring the Future (MTF): A Continuing Study of American Youth
overview and methods, 131–133, 211–212
academic achievement, 161–162
cigarette smoking
current prevalence, 174–175, 187–189, 229–230, 233
expectations to smoke, 183–184, 249–251
initiation of smoking, 180, 244, 704
intensity of smoking, 175–177, 190, 236–237, 365
intentions to smoke, 512–513
prices, 702, 704–706
smoking cessation, 368
substance use comorbidity, 193, 263–264, 276, 371
trend data, 138–142, 164, 185–191, 257, 345–353
cigar smoking, 149
clean air policies, 709
marketing exposure, 529, 561
movie smoking, 567–569
multiple tobacco product use, 207–209, 262, 276, 289–290
perceived health risks, 191–192, 368, 392
perceptions of smoking, 192, 369–371
school tobacco policies, 788
smokeless tobacco use
age at onset, 201, 291
ever used, 199–200, 267–268
substance use comorbidity, 203, 276, 371
substance use comorbidity, 193, 263–264, 276, 371
tobacco control funding, 696
tobacco use disparities, 149, 153
tobacco use measures, 216–217, 415–424
mood, 445–447
Motion Picture Association of America (MPAA), 570, 598
motivational approaches, 731
Mountain Dew (brand), 548
movie smoking, 565–598
content analysis, 566, 571–574
depictions of smoking, 567–570
as environmental factor, 437–438
experimental research, 596–598
exposure assessment, 571–574
historical links between tobacco industry and, 565–566
identity development and, 564
media company responses, 570–571
movie ratings, 564, 569–571, 574, 593–596, 598
movie stars as role models, 564, 571, 597
movie trailers, 571
population-based research, 575–596
cross-sectional studies, 575, 593
longitudinal studies, 575–592
mediation pathways, 592–593
moderation effects, 592
parental control over media exposure, 593–596
summary, 593
product placement, 565–567
as stream of influence, 511
summary, 598, 601, 852
MPAA. See Motion Picture Association of America
MPP. See Midwestern Prevention Project
MSAs. See metropolitan statistical areas
MTF. See Monitoring the Future
multilevel models, 459
multiple-baseline studies, 634
multiple tobacco product use
current trends, 850
MVPA. See moderate-to-vigorous physical activity
myocardial infarction (MI), 199
My Smokers’ Rights (Web site), 548–550
MySpace, 550, 688
nAChRs. See nicotinic acetylcholine receptors
narratives, in antismoking strategy, 637
National Association of State Boards of Education (NASBE), 552–553
National Cancer Institute (NCI)
ASSIST, 694, 696, 786
COMMIT, 693
smoking prevention criteria, 553
tobacco control monographs, 5, 23, 26, 517, 564, 601, 715, 852
Youth Smoking and the Media study, 558, 636–637, 686–688, 691
National Center for Chronic Disease Prevention and Health Promotion (CDC), 7
National Center for Health Statistics (CDC), 212
National Education Longitudinal Study (NELS), 703–705
National Health and Nutrition Examination Survey (NHANES), 197, 707, 710
National Health Interview Survey (NHIS)
overview and methods, 132–134, 212
body mass index, 197
smoking trend data, 141–142, 188–189, 258–260, 359–363
National Heart, Lung, and Blood Institute Growth and Health Study, 64
National Institute on Drug Abuse (NIDA), 539
National Institutes of Health (NIH), 554, 854
National Longitudinal Study of Adolescent Health (Add Health)
overview and methods, 132–134, 212
socioeconomic factors, 434
stages of smoking behavior, 182–183, 246–248
trajectories of smoking, 180–181, 245–247, 344
weight control behavior, 66
National Longitudinal Survey of Youth (NLSY), 66, 703–704
National Registry of Evidence-based Programs and Policies, 791
National Smokers Alliance, 550
National Survey on Drug Use and Health (NSDUH)
overview and methods, 131–133, 213
cigarette smoking
age at onset, 134–136, 179–180, 191, 238, 244
brand preferences, 161, 163, 177–178, 190, 241–242, 366–367
ever smoked, 173–174, 227–228
initiation of smoking, 179–180, 261
intensity of smoking, 175–177, 234–237
nicotine dependence, 184–185, 252–256
trend data, 138–143, 185–191, 294
cigar smoking
brand preferences, 282–283, 285–286
current prevalence, 142, 146, 149, 151, 203–205, 280–281, 393–398
ever used, 203, 279
substance use comorbidity, 287
clean air policies, 709
depression, 198, 266
multiple tobacco product use, 276, 287–290, 404
smokeless tobacco use
age of onset, 291–293
brand preferences, 273–274
ever used, 199–200, 267–268
substance use comorbidity, 203, 276
susceptibility to smoking, 179, 185, 243
tobacco use disparities, 149–154
tobacco use measures, 216–217, 415–424
National Tobacco Control Program, 694, 696
National Youth Risk Behavior Survey. See Youth Risk Behavior Survey (YRBS)
National Youth Tobacco Survey (NYTS)
overview and methods, 131–133, 213–214
cigarette smoking
age at onset, 244
current prevalence, 135, 137, 139, 229–230
ever smoked, 173–174, 227–228
intensity of smoking, 234–237
mentholated cigarettes, 178
trend data, 138–142
cigar smoking
ever used, 203, 279
prevalence, 142, 145, 149, 203–205, 280–281
prices, 706
digital marketing exposure, 551
multiple tobacco product use, 155, 207–209, 289–290
smokeless tobacco use
age at onset, 201, 272
current prevalence, 142, 144, 200–201, 269–270
ever used, 199–200, 267–268
specialty cigarettes (bidis & kretaks), 206–207, 288, 400–403
tobacco use measures, 216–217, 415–424
Native Americans. See American Indians
naturalistic exposure studies, 558, 561–562, 669–682, 686–688
NCI. See National Cancer Institute
NDSS. See Nicotine Dependence Syndrome Scale
negative affect, 445–447, 451
neighborhoods
socioeconomic factors, 434
tobacco outlets in, 436–437
NELS. See National Education Longitudinal Study
health warnings, 717
lung function studies, 83
neurobehavioral systems, 428
neurobiological processes, 451, 455–459
neurodevelopmental processes, 451, 456–459
neurotransmission
candidate gene studies, 452
effects of nicotine on, 455–456, 459
neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene, 452
Newport (brand)
ad campaigns, 519, 521, 537
point-of-sale advertising, 529
newspaper advertising, expenditures on
  cigarettes, 489, 491–493
  smokeless tobacco, 501–502
New York Tobacco Control Program (NYTCP), 696–697, 853
New Zealand
marketing practices, 513, 532
movie smoking, 598
respiratory disease, 94
socioeconomic factors, 434
weight control behavior, 45
NHANES. See National Health and Nutrition Examination Survey
NHIS. See National Health Interview Survey
nicotine addiction, 23–29
clinical diagnosis of, 23–24
development of, 24–27, 429–430
epidemiology, 179–185, 245–248, 344
epidemiological patterns, 184–185, 252–256
epidemiology, 184–185, 252–256
molecular genetics, 184–185, 252–256
measurement of, 23–24, 456
neurobiological effects of, 451, 455–459
product design enhancing, 535–539
withdrawal symptoms, 23–24, 456
Nicotine Dependence Syndrome Scale (NDSS), 24, 184
nicotine metabolism, genetic influences on, 26, 452
nicotine replacement therapy, 635, 800, 807
Nicotine & Tobacco Research, 177
nicotinic acetylcholine receptors (nAChRs), 455
nicotinic receptor genes, 452
NIDA. See National Institute on Drug Abuse
nightclubs, promotional activities in, 522, 534
NIH. See National Institutes of Health
NLSY. See National Longitudinal Survey of Youth
noncurrent established smokers, 430
noncurrent experimenters, 430
non-participating manufacturers (NPMs), 525–526
non-susceptible stage, 430
norms (social)
  large social environment, 431–433, 437–439, 509
  peer group, 443
  smoking prevention and, 632, 635, 686–690
North Carolina Youth Empowerment Study, 790
North Karelia Youth Project (Finland), 637, 692, 785
Norway
  family interventions, 721, 726
  marketing influences, 512
  respiratory disease, 91
Not On Tobacco (N-O-T) program, 800–801
NPMs. See non-participating manufacturers
NSDUH. See National Survey on Drug Use and Health
NTRK2. See neurotrophic tyrosine kinase receptor type 2 gene
nutrition, 196, 379–380
NYTCP. See New York Tobacco Control Program
NYTS. See National Youth Tobacco Survey
O

obesity, 196–198, 377–378
prevention of (See weight control)
OECD. See Organisation for Economic Co-Operation and Development
Office of Applied Studies (SAMHSA), 213
Office on Smoking and Health (CDC), 7
oligopoly, 523
online marketing. See digital marketing
online tobacco sales, 547–548
“onserts” (package), 534
onset of smoking. See initiation of smoking
open source marketing, 548
OPMs. See original participating manufacturers
oppositional defiant disorder; 27–28
oral cancer, 199, 806, 808
Oregon, tobacco control program, 694
Oregon Research Institute, 803
Oregon Social Learning Center, 720
Organisation for Economic Co-Operation and Development (OECD), 514
organized activities, 437, 455
original participating manufacturers (OPMs), 525–526
outdoor advertising
  antismoking messages, 688
  tobacco industry expenditures on
    cigarettes, 489, 491–493
    smokeless tobacco, 501–502
oxidative stress, 95–96
packaging, 530–535
   imagery on, 530–533, 535
   industry expenditures on, 488, 507
   links to other marketing, 533–535
   plain (standardized), 532–533
   in response to tobacco control, 534–535
   risk perception and, 531–532
   shape and size, 533–535
   smokeless tobacco products, 531, 533, 540–541
   summary, 535, 599–600
   warnings on (See health warnings)
PAHO. See Americas (PAHO)
Pall Mall (brand), 535
parental behavior. See also family
   control over media exposure, 593–596
   gene-environment interaction, 454–455
   home smoking policies, 709–710
   influence of, 444, 519–520, 553, 720
parental education
   as cultural influence, 433–434
   current smoking prevalence by, 175, 233
   smokeless tobacco use, 200–201, 271
   smoking trend data by, 189
   tobacco use disparities by, 153
parental smoking
   health effects of (See prenatatal exposure; secondhand smoke)
   movie smoking and, 592
   psychosocial influence of, 443–445
   parenting style, 444
Parent on Your Side program, 721
“Parents. The Best Thing Between Kids and Cigarettes” campaign, 557
Parliament (brand), 521
passive smoking. See secondhand smoke
Pathobiological Determinants of Atherosclerosis in Youth (PDAY), 97–102
patterns of smoking. See intensity of smoking
PayPal, 548
PDAY. See Pathobiological Determinants of Atherosclerosis in Youth
peer groups
   versus family context, 444–445
   gene-environment interaction, 454
   homogeneity of tobacco use, 439–441, 520
   interaction-based versus identity-based, 441–443
   marketing interplay with, 519–522, 599
   movie smoking and, 592–593
   smoking prevention, 632–633, 786
      school environment (See school-based programs)
      youth empowerment and activism, 789–792
PepsiCo, 548
perceived health risks
   cognitive processes, 448
   epidemiology, 191–192, 368, 392
   health warnings and, 715–719
   packaging and, 531–532
   as risk factor, 427–428
   smokeless tobacco use, 428, 806, 808
   smoking prevention programs and, 561
perceptions of smoking. See attitudes toward smoking
periodontal disease, 199
peripheral processing systems, in communication theory, 636
personality traits, 632
personal risk factors, 427, 632–634
persuasion, communication theories of, 636, 686
PFDY. See Preparing for the Drug Free Years program
pharmacies, point-of-sale advertising in, 545
pharmacologic adjuncts for cessation, 635, 800, 807
phenotypes
   definition of, 451
   genomic sequencing, 453
   initiation of smoking affected by, 26
   twin studies, 453–454
Phenotypes and Endophenotypes: Foundations for Genetic Studies of Nicotine Use and Dependence (NCI Monograph 20), 23, 26
Philip Morris, 488
   brand-specific marketing, 516, 520–522
   corporate website, 546, 548, 553
digital marketing, 547–548
Marlboro brand (See Marlboro)
packaging strategies, 534
Parliament brand, 521
pricing strategies, 523–525, 527
product design, 535–539
promotional allowances, 491, 542
smokeless tobacco products, 539–540
smoking prevention programs, 553–555
   mass media, 557–563, 635, 687
   youth access, 555–557
Phillies (brand), 205, 282, 284–285
pH modifiers, 539, 541
physical activity, 196, 379
physical environment, large, 437–438, 458
pictorial health warnings, 717–719, 810
Pinkerton Tobacco Co., 548. See also Red Man
pipe tobacco, taxes on, 698
pipe use, 430, 454
plain packaging, 532–533
plasticity of development, 632
point-of-sale marketing, 541–545
   adolescent tobacco use linked to, 544
   bans on, 534, 545
   convenience stores, 543–544
density of retail outlets, 544–545
   as environmental risk factor, 437
   expenditures on, 489, 491–493, 501–502, 541
   packaging as, 534
   policy options, 545
   price promotions, 528–529
   product location, 542
   summary, 545, 600
Pollay, R.W., 521
population density
  current smoking prevalence, 175, 233, 271
  smokeless tobacco use, 201
population surveys. See also specific survey
  validity of, 215
Portugal, academic achievement, 161
possession, use, and purchase (PUP) laws, 696, 702, 711–712
postmortem studies, atherosclerosis, 97–101
poverty. See socioeconomic status
powerwalls, 534
precontemplation stage, 430
prenatal exposure
  DNA damage, 21–22
  lipid levels, 109
  low birth weight, 96, 108
  neurodevelopmental processes, 457, 459
  vascular injury, 96–97
preparation stage, 430
Preparing for the Drug Free Years (PFDY) program, 725–726
prevalence. See epidemiology
Prevent all Cigarette Trafficking Act (2009), 548
prevention programs. See also specific program
  cigarette smoking (See smoking prevention)
  conclusions, 10, 812
  evaluation methods, 213, 558–561, 633–634, 636
  evidence summary, 809–811
  smokeless tobacco use, 801–804
price discrimination, 528
price elasticity of demand, 699–706
price leadership, 523
price promotions
  definition of, 713
  impact on tobacco use, 528–529
  industry expenditures on
    cigarettes, 488–494, 497–500
    smokeless tobacco, 501–503, 505–506
  in response to tobacco control, 527–528
  tax increases and, 526–527
pricing, 522–530
  cigars, 155, 706
  impact on tobacco use, 528–529, 699–706, 809
    initiation of smoking, 529, 704–705
    intensity of smoking, 702–704, 706
    smoking cessation, 705
    smoking prevalence, 526, 701
  marketing expenditures and, 488
  in response to tobacco control, 527–528
  sales data by price, 525
  sensitivity of youth smokers to, 527–528, 534–535, 699–706
  since Master Settlement Agreement, 513–514, 525–528, 530
  smokeless tobacco, 202, 706, 802
  strategies, 523–528
  summary, 529–530, 851
  taxes and, 523–524, 526–527, 699–707
Pride Surveys, 720
Prime Time Little Cigars (brand), 283
print advertising, expenditures on
  cigarettes, 489, 491–493
  smokeless tobacco, 501–502
processing systems, in communication theory, 636
Pro-Children Act (1994), 788
product design. See also packaging
  cigarettes, 335–359, 600
  smokeless tobacco, 539–541, 600
  summary, 541, 851
product labeling
  brand descriptors, 31, 530–532, 697
  public health (See health warnings)
product placement (promotional allowances)
  definition of, 713
  expenditures on
    cigarettes, 489, 491–493, 497–500
    smokeless tobacco, 501–502, 505–506
  movies, 565–567
  retail outlets, 542, 600
  summary, 852
Programs to Advance Teen Health, 802
Project CHIPS (Choosing Healthy Influences for a Positive Self), 787
Project FLAVOR (Fun Learning about Vitality, Origin, and Respect), 787
Project MYTRI, 786
Project SHOUT (Students Helping Others Understand Tobacco), 785, 803
Project Sixteen, 802
Project SMART (Self-Management and Resistance Training), 787, 789
Project STAR (Students Taught Awareness and Resistance) program, 725
Project Towards No Tobacco Use (TNT), 791, 803
promotional activities, 508–522. See also marketing practices
  bans on (See advertising bans)
    in bars and nightclubs, 522, 534
    definition of, 713
  expenditures on
    cigarettes, 490–493, 495–496
    smokeless tobacco, 501–507
  initiation of smoking and, 515–516
  “Marlboro Friday,” 488, 523–525
  movie tie-ins, 565
  on packaging, 534
  summary, 487, 508–509, 851–852
prosmoking Web sites, 548–551
protective factors, 428, 444, 509, 631
proximate factors, 509–511, 632–633
psychiatric disorders, 27–28, 195–196
psychosocial approaches, 731
psychosocial risk factors, 427
public entertainment sponsorships
  bans on, 491, 534
  expenditures on
    cigarettes, 490–492, 494, 497–500
    smokeless tobacco, 501–507
  promotion of, 534
Public Health Cigarette Smoking Act (1969), 547
public housing, clean air policies, 710
public spaces, smoking in. See clean air policies
puffed tobacco filler, 537
puffers, 430
pulmonary function. See lung function; respiratory consequences
pulsing technique, 713
PUP. See possession, use, and purchase laws

Q

quality-adjusted life year (QALY), 791
quitting
  cigarettes (See smoking cessation)
  smokeless tobacco use, 804–808

R

racial/ethnic groups
  antismoking campaigns, 690
  cardiovascular consequences, 109
cigarette smoking
  age of onset, 191
  brand preferences, 161, 177–178, 239–242, 537
  current prevalence, 136–138, 164, 174–175, 177, 229–232, 364
    trends in, 187–190, 352–353
  disparities, 149–154
  ever smoked, 173–174, 186, 227–228
  intensity of smoking, 176, 234–237
  knowledge and attitudes, 192, 370
  nicotine dependence, 184–185, 252–255
  susceptibility to smoking, 179, 243
  trajectories of smoking, 181–182, 245–247
cigar smoking
  brand preferences, 205, 282–283, 285–286
  ever used, 203, 279
trend data, 399
clean air policies, 707
clinical interventions, 728
cultural influences, 432–433
depression, 198, 266
family context, 444
lung cancer rates, 188
movie smoking, 569, 575, 591–592
peer group influences, 439
point-of-sale marketing and, 542–543
price sensitivity, 705
respiratory consequences, 83–86, 88
school-based programs, 787
smokeless tobacco use
  age of onset, 291–293
  brand preferences, 273–274, 277–278
  current prevalence, 142, 144–149, 164, 200, 202, 269–270, 387, 391–392
  ever used, 199–200, 267–268
  prevention programs, 803–804
specialty cigarettes (bidis & kreteks), 206–207, 288, 400–403
Surgeon General’s Report (1998) on, 4
weight control
  beliefs about, 32–43
  epidemiologic findings, 157–161, 197–198
  initiation of smoking, 67, 79
  smoking behavior, 56–58
  smoking cessation, 69, 75
youth access, 712
Racketeer Influenced and Corrupt Organizations (RICO) Act (1970), 508
radio
  advertising ban, 635
  antismoking messages, 635, 688
Raising Kids Who Don’t Smoke (brochure), 553
randomized controlled trials (RCTs)
  advertising impact, 713–714
  movie smoking impact, 597–598
smokeless tobacco use prevention, 802, 807
smoking prevention, 634, 692–693
cessation programs, 793, 800
clinical interventions, 730
family interventions, 721–727
school-based programs, 732–734, 786
“Real Parents. Real Answers” program (Web site), 553
recall studies
  antismoking campaigns, 686–689
  health warnings, 715–718
  movie smoking, 571, 575
recent acquisition stage, 430
Red Man (brand)
  market share, 201, 273, 275, 277
  Web site, 548
Red Seal (brand), 273, 275, 277
refusal skills training program (Biglan), 726
regional variations. See United States regional variations
regulation. See also specific law
  advertising bans (See advertising bans)
  clean air (See clean air policies)
national, 854
  public health (See health warnings)
  recommendations, 853–856
taxes (See taxation)
tobacco control (See tobacco control policies)
youth access, 710–712, 810
relative improvement (RI) rates, 721–726, 785
religion
  influence on smoking behavior, 431–432
smokeless tobacco use and, 201, 271
smoking prevalence and, 175, 233, 431–432
replicated moderation effects, 592
respiratory consequences, 79–94
  chronic symptoms and diseases, 87–94 (See also specific disease or symptom)
evidence review methods, 80
genetic factors, 86
lung growth, 80–87
retail outlets
  advertising in (See point-of-sale marketing)
  convenience stores, 543–544
density of, 437, 544–545
  online tobacco sales, 547–548
prices (See pricing)
in school neighborhoods, 436–437, 529, 543–545
  youth access, 555–557, 710–712, 810
retail-value-added promotions. See price promotions
Revel (brand), 533
reverse causality, 714
reward pathways, 455–456
Reynolds American, Inc., 488
  brand-specific marketing, 516
  Camel brand (See Camel)
corporate website, 546, 548
digital marketing, 546–550
Kool brand (See Kool)
Pall Mall brand, 535
pricing strategies, 524, 528
product design, 535–539
Salem (brand), 537–538
sales. See retail outlets
SAMHSA. See Substance Abuse and Mental Health Services Administration
sampling, expenditures on
cigarettes, 489, 491–493
smokeless tobacco, 501, 503
Santa Fe Natural Tobacco Company, Inc., 488
Satcher, David, 853
Scandinavian Asthma Genetic Study, 86
schizophrenia, 27–28
school-based programs, 731–792
  approaches used in, 731–732
cost-effectiveness of, 791
effectiveness of, 731–732
  antitobacco policies, 787–788
cultural sensitivity, 787
evidence-based practice, 787
ineffective programs, 788–789
meta-analyses, 732–734
recent studies, 786
short- and long-term effects, 734–786
summary, 786–787, 811
evaluation methods, 634
industry-sponsored, 554–555
smokeless tobacco use, 802–807
smoking cessation, 799–800
summary, 791–792, 811
theories underlying, 633–634
youth empowerment and activism, 789–792
school-based surveys. See also specific survey
data collection methods, 131
validity of, 215
school environment, 435–437
  antitobacco policies, 435, 707–709, 787–788
gen–environment interaction, 455
neighborhood tobacco outlets, 436–437, 529, 543–545
peer social networks within, 441–442
School Health Policies and Programs Study (CDC), 435
SCQ. See Smoking Consequences Questionnaire
scientific reviews, 4–5. See also specific review
screening. See clinical interventions
SEARO. See South-East Asia
secondhand smoke
  cardiovascular effects, 96–97, 108
  exposure to, 6, 15
  fetal effects, 21–22, 96–97
indoor air (See clean air policies)
smoking prevention and, 635
Surgeon General’s Report (2006) on, 6, 15
selection, peer pressure and, 520
self-efficacy, 447–448, 509, 632
self-help booklets for families, 552–553
self-identity, 564, 632–633
self-image, 509, 512, 633
self-reported data, validity of, 215, 713
self-service cigarette displays, 543
sensation seeking
antismoking campaigns and, 690–691
movie smoking and, 592
sensory transfer, 532
serotonin pathway genes, 26, 452
SES. See socioeconomic status
SEU. See subjective expected utility
sexual activity, 195, 375
siblings, smoking by, 444
single nucleotide polymorphisms (SNPs), 452
situational factors, 215
size of packaging, 533–535
Skoal (brand)
dissolvables, 507
market share, 164, 201–202, 273, 275, 277
product design, 540
Web site, 548
“slim” descriptors, 31, 530–531
“slim” packaging, 533
small social groups. See also family; peer groups
influences of, 439–445, 458
smoking prevention in, 719–720
“SMART (Skills Mastery and Resistance Training) Moves”
program, 555
Smee Report (UK), 513
smoke
product design and, 535–539
secondhand (See secondhand smoke)
Smoke-free Kids program, 721, 725–726
SmokeLess States, 694, 696
Smokeless Tobacco Master Settlement Agreement (1998), 507
smokeless tobacco products
definition of, 6
digital marketing, 548–549
electronic cigarettes (e-cigarettes), 155, 549–551
flavor additives, 539
health warnings, 810
marketing expenditures, 491, 501–507
packaging, 531, 533, 540–541
pricing, 202, 706, 802
product design, 539–541, 600
taxes on, 698
tobacco control policies, 802
smokeless tobacco use
academic achievement and, 161–162
age at onset, 201, 272, 291–293
brand preferences, 164, 201–202, 273–275, 277–278
cessation of, 804–808
current prevalence, 142, 144, 146, 164, 200–201, 269–271,
374, 382–388
etiology of, 430
ever used, 199–200, 267–268, 392
genetic factors, 454
health consequences, 199, 428, 806, 808
initiation of, product design for, 539–541
knowledge and attitudes about, 427–428
measures of, 216–217, 419–421
multiple tobacco product use, 154–155, 165, 207–209, 262,
287, 289–290, 404
prevention of, 801–804
substance use comorbidity, 193–194, 276, 371
trend data, 144–149, 195, 202, 293–294, 389–392
The Smoker’s Club (Web site), 550
smokers’ rights groups, 548–551
smoking
cigars (See cigar smoking)
definition of, 6
health consequences of (See health consequences)
reasons for (See etiology of tobacco use)
statistics on (See epidemiology)
smoking behavior
acquisition of (See initiation of smoking)
first use (See age at onset)
heritability of (See genetic factors)
movie depictions of (See movie smoking)
number per day (See intensity of smoking)
psychosocial factors (See etiology of tobacco use)
quitting (See smoking cessation)
trajectories of
developmental stages, 429–430
epidemiology, 180–181, 245–248, 344
risk factors, 428–429
transitions in, 181–183, 246, 248
Smoking Beliefs and Attitudes Questionnaire, 44
smoking cessation, 792–801
attempts at
definition of, 216, 419
epidemiology, 191, 262, 317–327, 368, 411–412
developmentally appropriate programs, 792
electronic technology, 800–801
intensity of smoking and, 184
lung function and, 83
pharmacologic adjuncts, 635, 800
pricing and, 705
program effectiveness, 792–800
summary, 801
weight gain after, 59, 69–70, 75–77
Smoking Consequences Questionnaire (SCQ), 42–43, 447
Smoking Lobby (Web site), 550
smoking prevention
approaches to, 632–633, 731–732
clean air (See clean air policies)
clinic-based (See clinical interventions)
community interventions, 692–693, 811
youth empowerment and activism, 789–792
suicidal ideation, 195–196, 376
“Support the Law...It Works!” program, 555
Surgeon General’s Report (1964), 95, 431, 714, 849
Surgeon General’s Report (1979), 849–850
Surgeon General’s Report (1983), 95
Surgeon General’s Report (1990), 69–70
advertising imagery, 574
continuum of smoking behavior, 181
developmental stages, 429, 509
epidemiology, 131, 134, 156, 164, 185, 189, 191
health consequences, 15–16, 79–80, 87, 95
psychosocial risk factors, 427–428, 519
smokeless tobacco use, 201, 208
smoking prevention programs, 631, 637, 683, 731
substance use, 193
taxation since, 698
tobacco industry marketing, 487
youth access, 710
Surgeon General’s Report (2001), 4, 512
Surgeon General’s Report (2004), 4, 7
health consequences, 16–17, 20, 80, 87, 95, 108
Surgeon General’s Report (2006), 6, 17–21, 95
Surgeon General’s Report (2010), 4
 genetic influences, 451
 health consequences, 86, 95
 nicotine addiction, 23, 26
 conclusions, 8–10 (See also conclusions)
evidence evaluation, 7–8
 focus of, 6
 organization of, 6–7
 preparation of, 7
surveillance systems, 131–133
susceptibility to smoking
epidemiology, 179, 185, 243, 295–305
marketing influences, 512–513, 515, 520
stage models, 181–182, 429–430
Sweden, health consequences, 94, 199
Swedish council for Information on Alcohol and Other Drugs, 210
Sweet Dreams (brand), 205
Swisher Sweats (brand), 205, 282, 284–285
SYMATU. See Statewide Youth Movement Against Tobacco Use
Synar Amendment (ADAMHA Reorganization Act), 631, 710–712, 810, 854

“Talk. They’ll Listen” campaign, 557, 561, 635
TAPP. See Tobacco and Alcohol Prevention Project
target rating points (TRPs), 689, 853
Task Force on Community Preventive Services, 695, 734
taxation, 697–707
 avoidance of, 706
 federal, 698–699
 impact on tobacco use, 699–706
 online tobacco sales, 547
 pricing and, 523–524, 526–527, 699
 state and local, 699–700, 704
 summary, 706–707
Teague, Claude E., Jr., 536
Teenage Attitudes and Practices Survey, 43, 198
Teitelbaum, Shari, 521
telephone advertising, expenditures on, 491, 493–494, 502–503
telephone-based cessation programs, 801, 807
television advertising
 ban on, 507, 635
econometric analyses of, 514
imagery in, 437–438
smoking prevention programs, 553, 557–563, 688
television viewing, prevalence of, 196, 378
Tempo (brand), 521
temporal relationship of association, 7
testimonials, expenditures on, 490, 501, 503
Test Pilot (movie), 565–566
Texas, tobacco control program, 694, 853
text messaging, smoking cessation using, 801
Thailand
 health warnings, 719
 marketing practices, 534, 545
Theory of Planned Behavior (TPB), 509, 599, 636
Theory of Reasoned Action (TRA), 509, 636
Theory of Triadic Influences (TTI), 428–429
impact of marketing, 509–510, 512, 516, 599
smoking prevention theories based on, 632–634, 809
“thin” descriptors, 31, 530–531
“Think. Don’t Smoke” campaign, 554, 557, 561, 635, 687
thrombosis, 96
Thumbs Up! Thumbs Down! (TUTD) Project, 569
tie-ins, tobacco/movie industry, 565
Timber Wolf, 274–275, 278
time-series studies
 marketing, 514, 713, 715
smoking prevention, 634
Time Warner, 570
TNT. See Project Towards No Tobacco Use
To Have and Have Not (movie), 565
Tobacco: Helping Youth Say No (brochure), 553
Tobacco and Alcohol Prevention Project (TAPP), 785
tobacco control policies
 antismoking campaigns (See smoking prevention)
clean air (See clean air policies)
history of, 849–850
Internet campaigns against, 548–549
marketing practices and
movie smoking, 571, 598

TagSNPs, 452
“Take 10” campaign, 557
Taking Action to Reduce Tobacco Use (IOM), 4

896
Preventing Tobacco Use Among Youth and Young Adults

packaging, 534–535
point-of-sale, 545
pricing, 527–528
product design, 541
recommendations, 853–856
since 1994 Surgeon General's Report, 3–4, 852
smokeless tobacco, 802
state-level, 694–697, 811, 849, 853
taxes (See taxation)
youth access programs, 555–557, 710–712, 810
tobacco industry. See also specific company or brand
attitudes toward, 554–555, 558–559, 635
conclusions, 10, 601–602
evidence summary, 598–601
marketing by (See marketing practices; specific practice)
position and behavior of, 517–522
retailers (See retail outlets)
smoking prevention programs, 552–564
community partnerships, 555
competition with marketing, 511
industry paradigm shift, 552–553
mass media, 557–563, 635, 687
sales to minors prevention, 555–557
school-based, 554–555
self-help booklets for families, 552–553
summary, 563–564, 601
summary, 487, 851
Tobacco Institute
Helping Youth Decide booklet, 552–553
"It's the Law" program, 555–557
smoker’s rights campaigns, 550
"Tobacco is Whacko if You’re a Teen" campaign, 557, 561, 635
Tobacco Product Scientific Advisory Committee (TPSAC), 539
tobacco use
cigarettes (See smoking)
cigars (See cigar smoking)
definition of, 6
disparities in, 149–154
international statistics on (See worldwide tobacco use)
measures of, 215–217, 415–424
prevention of (See prevention programs; smoking prevention)
recent trends in, 850–852
risk factors for, 427–429 (See also etiology of tobacco use)
smokeless (See smokeless tobacco)
Tobacco Use Supplement to the Current Population Survey, 177, 435, 705, 707–708
tombstone advertising, 557
tooth decay, 199
TPB. See Theory of Planned Behavior
TPSAC. See Tobacco Product Scientific Advisory Committee
TRA. See Theory of Reasoned Action
Tracy, Spencer, 565–566
trademarks, on packaging, 530, 532–533
trajectories of smoking
developmental stages, 429–430
epidemiology, 180–181, 245–248, 344
risk factors, 428–429
transit advertising, expenditures on, 489, 491–493
transitions in smoking behavior, 181–183, 246
amount smoked (See intensity of smoking)
cessation (See smoking cessation)
effect of prices on, 703–706
initiation (See initiation of smoking)
Transtheoretical Model, 181
trend data
cigarette smoking, 138–143, 185–191, 257–260, 294, 345–363
cigar smoking, 149–151, 195, 205, 294, 399
smokeless tobacco use, 144–149, 195, 202, 293–294, 389–392
TRPs. See target rating points
“truth” campaign (American Legacy Foundation), 558, 561, 635, 687–690, 850
TTI. See Theory of Triadic Influences
TUTD. See Thumbs Up! Thumbs Down!
Turkey
academic achievement, 161
endothelial dysfunction, 108
twin studies
dyslipidemia, 108–109
geneic factors, 453–454
Twitter, 549

U

ultimate factors, 509–511, 632
United Kingdom (UK)
health consequences, 88, 91, 102
marketing practices, 512–513, 517, 531–533
movie smoking, 569, 574
smoking prevention programs, 687, 692, 721, 786
weight control behavior, 32, 57, 63, 70
United States Junior Chamber, 555
United States regional variations
cigarette smoking
brand preferences, 177–178, 239–242
current prevalence, 175, 229–230, 339–343, 354–358
ever smoked, 174, 227–228
intensity of smoking, 176, 234–237
cigar smoking
brand preferences, 282–283, 285–286
current prevalence, 204–205, 280–281, 393–394, 396–398
ever used, 279
clean air policies, 708
smokeless tobacco use, 199–200, 267–268, 273–274, 382–386, 803
   brand preferences, 201–202, 277–278
U.S. Census Bureau, 706
U.S. Department of Agriculture (USDA), 199, 555
U.S. Department of Education, 787
U.S. Department of Health and Human Services (USDHHS)
   CDC (See Centers for Disease Control and Prevention)
   Healthy People objectives, 5, 135, 185, 711, 854
   strategic action plan, 854–856
   Substance Abuse and Mental Health Services
   Administration, 190, 213, 854
U.S. Food and Drug Administration
   authority of, 4, 207, 545, 547, 810, 852–854
   ban on flavorings, 164, 178, 205, 207, 539
   health warnings, 719, 810
   online sales/marketing regulations, 547–548
   “1996 rule” (advertising restrictions), 491
   tobacco advertising rules, 437, 557
   Tobacco Product Scientific Advisory Committee, 178
U.S. Postal Service (USPS), 548
U.S. Preventive Services Task Force (USPSTF), 727
U.S. Smokeless Tobacco, 531, 548. See also Copenhagen; Skoal
United States v. Philip Morris, 851
Universal, 570
UPS, 548
Uptown (brand), 537
“Upward Bound” program, 555

V

validity
   advertising impact studies, 438, 514, 713–714
   tobacco use measures, 215
vascular injury, 95–96
vascular reactivity, 102, 108
Vector Tobacco Inc., 488
vending machines, 437, 710
ventilated filters, 531, 536–537
ventral tegmental area (VTA), 455
video games, advertising in, 437–438, 546
violence, 195–196, 376–377
viral marketing, 552
Virginia Slims (brand), 31
Vital Statistics Natality, 702
Vlagtwedde/Vlaardingen study (Netherlands), 83
VTA. See Ventral tegmental area

W

Walgreens, 545
   “wallet packs,” 534–535
Washington State Institute for Public Policy, 791
water pipes (hookahs), 155, 206–207, 430

WCSS. See Weight Control Smoking Scale
Web sites. See also digital marketing; specific site
antismoking, 688
cessation programs, 800–801, 807–808
online tobacco sales, 547–548
prosmoking, 548–551
social networking, 549–551, 688
tobacco company, 548–549
   expenditures on, 490, 493–494, 502–503, 546
WE CARD Coalition, 556
   “We Card” program, 556–557
Wegmans, 545
weight control, 30–79
   advertising emphasizing, 31, 530–532
   beliefs about, 32–45
   evidence review methods, 30
   smoking behavior related to
   clinical studies, 60–63
   effectiveness of (See body weight)
   initiation of smoking, 63–68, 75–79
   population surveys, 45–60
   summary, 79
Weight Control Smoking Scale (WCSS), 57, 60
Western Pacific (WPRO), tobacco use, 209–210
   age of onset/ever smoked, 304–305, 407–408
   current prevalence, 326–327, 335–336, 409–410
   intensity of smoking, 315–316
   smoking cessation, 326–327, 411–412
   wheeze, 87–94
   cross-sectional studies, 88–91
   prospective cohort studies, 91–94
   summary, 94
White Owl (brand), 205, 282, 284–285
WHO. See World Health Organization
whole-genome sequencing, 453
Wilkerson Sword Company, 539
Winston (brand), 535–536
withdrawal symptoms, 23–24, 456
World Health Organization (WHO)
   atherosclerosis study, 100
   Framework Convention on Tobacco Control (FCTC), 531, 545, 719
   Global Tobacco Surveillance System (GTSS), 156, 209–210
   movie rating recommendations, 571, 598
   smoking prevention campaign study, 563
World Heart Federation, 100
worldwide tobacco use, 156–157, 165, 209–210. See also specific region or country
   age of onset/ever smoked, 295–305, 407–408
   current prevalence, 317–336, 409–410
   intensity of smoking, 306–316
   international surveillance systems, 131–133
   other forms of tobacco than cigarettes, 413–414
   regulatory actions, 854
   smoking cessation, 319–322, 411–412
WPRO. See Western Pacific
Yahoo!, 550
young adults
  cigarette smoking
    brand preferences, 161–164, 177–178, 190, 241–242, 507, 516
    current prevalence, 137–139, 164, 174–175, 177, 232, 339–344, 364
    developmental patterns, 179–185, 245–248, 344
    disparities, 149, 152–154
    initiation of smoking, 142–143, 179–180, 261
    intensity of smoking, 249–251
    nicotine addiction, 184–185, 254–256
    trend data, 141–143, 177, 185–191, 258–260, 294, 359–363
  cigar smoking
    brand preferences, 164
    current prevalence, 142, 146, 280–281, 393–398
    trend data, 149, 151, 294
  current trends, 850
  definition of, 6
  developmental risk factors, 428
  educational level, 435
  marketing aimed at, 508, 518–522
  peer group influences, 440
  price sensitivity of, 527–528, 704–705
  smokeless tobacco use
    brand preferences, 164, 277–278
    current prevalence, 142, 146, 201–202, 269–270, 382–388
    trend data, 144–149, 202, 292–294
  water pipes (hookahs), 206
  weight control
    beliefs about, 32–45
    smoking behavior, 45–60
young people, definition of, 6
youth access
  industry-sponsored prevention programs, 555–557
  physical environment, 437–438 (See also retail outlets)
  regulations on, 710–712, 810
youth empowerment and activism, 789–792
Youth Risk Behavior Surveillance System (YRBSS)
  overview and methods, 131, 214
  smoking trend data, 138–142
  tobacco use measures, 216–217, 415–424
  weight control behavior, 58, 157
Youth Risk Behavior Survey (YRBS)
  overview and methods, 131–133, 214
  cigarette smoking
    age at onset, 22, 180, 244
    current prevalence, 135, 137, 164, 174–175, 187–189, 229–230
    ever smoked, 173–174, 185–186, 227–228
    initiation of smoking, 180
    intensity of smoking, 175–177, 234–235, 237
    prices, 702–703
    projected rates, 854, 856
  cigar smoking, 145, 149–150, 203–205, 280–281, 399
  clean air policies, 709
  health-related behaviors, 194–197, 372–381
  multiple tobacco product use, 155, 207–209, 289–290, 404–406
  tobacco use disparities, 149, 154
  weight control behavior, 157, 160, 197
Youth Smoking and the Media study (NCI), 558
YouTube, 688
YRBS. See Youth Risk Behavior Survey
YRBSS. See Youth Risk Behavior Surveillance System